Vassiliki A. Papadimitrakopoulou, MD CV · CURRICULUM VITAE. Vassiliki A. Papadimitrakopoulou, MD . PRESENT TITLE AND AFFILIATION. Primary Appointment. Professor, Department of Thoracic/Head

CURRICULUM VITAE

Vassiliki A. Papadimitrakopoulou, MD

PRESENT TITLE AND AFFILIATION Primary Appointment

Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Jay and Lori Eisenberg Distinguished Professorship, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment N/A

CITIZENSHIP United States Greece

OFFICE ADDRESS The University of Texas MD Anderson Cancer Center 1515 Holcombe Boulevard Unit Number: 432 Houston, TX 77030 Phone: (713) 792-6363 Fax: (713) 792-1220 Email: [email protected]

EDUCATION Degree-Granting Education

University of Patras School of Medicine, Patras, Greece, MD, 1988, Medicine Postgraduate Training

Clinical Internship, Metaxas Cancer Hospital, Piraeus, Greece, 1989-6/1990 Clinical Residency, Institut Gustave Roussy, Paris, France, 1990-6/1992 Clinical Residency, Internal Medicine, Columbia Presbyterian Medical Center, New York City, 1991-6/1994 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1994-6/1997 Continuing Education, Heart of Leadership Course, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2007-2007 Continuing Education, Faculty Leadership Academy, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2008-2008 Continuing Education, The Path of Women Who Lead, Third WICR Leadership Development Workshop, American Association of Cancer Research, San Diego, CA, 2008-2008 Healthcare Management, Graduate Certificate in Healthcare Management, Rice University, Houston, TX, 2013-2014

CREDENTIALS


Page 2 of 47

Board Certification Internal Medicine, 1994-2004 Internal Medicine, Medical Oncology, 1997-2018

Licensures Active

Texas Medical Board, TX, K2553, 1/1997-8/2017 Inactive

Indiana Medical Board, IN, 01044764, 1/1996

EXPERIENCE/SERVICE Academic Appointments

Instructor, Department of Thoracic/Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997-1998 Assistant Professor, Department of Thoracic/Head & Neck Medical Oncology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998-2003 Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003-2009 Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009-present

Administrative Appointments/Responsibilities Deputy Section Chief, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, 2010-2011 Reviewer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-present Section Chief, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 Chair, Thoracic Multidisciplinary Planning Conference, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-present Section Chief, Thoracic Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015-present

Other Appointments/Responsibilities Organizer, Thoracic Section Multidisciplinary Protocol Review, Houston, TX, 2011-2013 Organizer, Thoracic Seminar Series, Houston, TX, 2011-2013 Clinical Research Committee Member, Vice Provost Advisory Council, Houston, TX, 2012 Working Group Member: Research Costs for Clinical Protocol Patients Committee, Vice Provost Advisory Council, Houston, TX, 2012 Member, The University of Texas MD Anderson Cancer Center Institutional Review Board, Houston, TX, 2014-present Study Section Member, The University of Texas MD Anderson Cancer Center Institutional Research Grant Program (IRG), Houston, 2014-present Chair, Clinical Trial Research Retreat/Beacon Build /Clinical Content Template Development Working Group, Houston, TX, 2017-present

Endowed Positions Jay and Lori Eisenberg Distinguished Professorship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014-present

Consultantships Telik Inc., USA, 2001


Page 3 of 47

Sanofi-Aventis, USA, 2003 Amgen, USA, 2006-2013 AstraZeneca, USA, 2006-present Genentech, USA, 2007-present Exelixis, USA, 2007 Merck & Co., USA, 2008-present Bristol Myers Squibb, USA, 2008-present Imclone, USA, 2008 Genentech-F. Hoffman La Roche, USA, 2009-present GlaxoSmithKline, USA, 2009 Medimmune, USA, 2011-present Clovis Oncology, USA, 2012-present Janssen Pharmaceuticals, USA, 2013-present Eli Lilly, USA, 2013-present Gensignia, USA, 2014 Biothera, USA, 2014 ARIAD, USA, 2016-present Novartis, USA, 2016-present Takeda Pharmaceuticals, USA, 2016-present Abbvie, USA, 2017-present Nektar Therapeutics, USA, 2017-present Araxes Pharma, USA, 2017 LOXO Oncology, USA, 2018 Arrys Therapeutics, USA, 2018

Military or Other Governmental Service N/A

Institutional Committee Activities Medical Practice, Subcommittee Member, 2003-2007 PDC/Pharmacology Users Committee, Member, 2005-2006 Clinical Translational Research Center (CTRC) Committee, Member, 2005-2006 Clinical Research Impact Subcommittee of the Clinical Council, Member, 2007-2010 Clinician Investigator Task Force, Member, 2007 Clinical Faculty Review Committee, Member, 2011-2014 Thoracic Cancer Multidisciplinary Program, Chair, 2011-present Investigational New Drug Committee, Member, 2012-present Clinical Faculty Review Committee, Vice Chair, 2012 Clinical Faculty Review Committee, Chair, 2013 Residual Funds Committee, Member, 2014-present Molecular Testing Evaluation Committee, Member, 2014-present Study Section Institutional Research Grant Program Committee (IRG), Member, 2014-present


Page 4 of 47

Institutional Review Board, Member, 2014-present IASLC Publications Committee, Member, 2015-present Promotion and Tenure Committee, Member, 9/2016-present Institutional Review Board, Vice Chair, 2017-present

HONORS AND AWARDS Scholarship Awarded: Stipend of the Greek State, 1982 Research Funds Competition Award, The University of Texas MD Anderson Cancer Center, 1996-1997 Clinical Oncology Merit Award, American Society of Clinical Oncology (ASCO), 1997 Division of Medicine Achievement in Research Award, The University of Texas MD Anderson Cancer Center, 1997 Pharmacia & Upjohn's Award for Outstanding Achievement in Cancer, 1997 Young Investigator Award, American Society of Clinical Oncology (ASCO), 1998 Clinical Research Career Development Award, American Society of Clinical Oncology (ASCO), 2000 Division of Medicine Team Science Award, The University of Texas MD Anderson Cancer Center, 2011 World Wide Who's Who Executives and Professionals in Research, Medicine and Healthcare, 2013 AACR Princess Takamatsu Memorial Lectureship Award Selection Committee, American Association for Cancer Research (AACR), 2014 Doctors of Excellence, Leaders in Healthcare Network, 2014 Excellence in Collaboration and Innovation Award, Bonnie Addario Lung Cancer Foundation, 2014 Appointment to FDA Center for Drug Evaluation and Research's ODAC, United States Federal Drug Agency (FDA), 2015-present Panelist, FDA NSCLC Blueprint 2020 Symposium, 2015 Irwin H. Krakoff Award of Excellence in Clinical Research, The University of Texas MD Anderson Cancer Center Center - Division of Cancer Medicine Faculty Award, 2017 Waun Ki Hong Award of Excellence in Team Science, The University of Texas MD Anderson Cancer Center Center - Division of Cancer Medicine Faculty Award, 2017 Addario Lectureship Award, Bonnie J. Addario Lung Cancer Foundation, 2018

RESEARCH Grants and Contracts

Funded Principal Investigator, 4%, SWOG S1400 Study Chair Funding, Oregon Health Science University, 11/20/2013-12/31/2019, $42,000 ($21,000/year) Co-Investigator, 5%, Targeting KRAS Mutant Lung Cancers, American Association for Cancer Research (AACR), PI - Heymach JV, 8/1/2015-7/31/2019, NCE ($580,000/year) Principal Investigator, 17%, SWOG - CTI, The Hope Foundation, 1/1/2016-12/31/2019 ($61,320/year) Collaborator, 2%, Defining and Defeating Mechanistic Subtypes of KRAS-mutant Lung Cancers, RP160652, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Jonathan Kurie, 6/1/2016-5/31/2021, $1,420,500 ($284,100/year) Principal Investigator, 4%, A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination with


Page 5 of 47

Carboplatin + NAB-Paclitaxel for Chemotherapy -Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer, Genentech, 6/27/2016-11/19/2018 ($658,068/year) Principal Investigator, 2%, A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer, Novartis, 6/29/2016-12/31/2020, $355,094 ($355,094/year) Principal Investigator, 1%, An Open-Label, Phase I Study of the Safety and Immunogenicity of JNJ-64041757, a Live Attenuated Listeria monocytogenes Immunotherapy, in Subjects With NSCLC, Janssen Research and Development, 8/4/2016-2/1/2019, $238,845 ($238,845/year) Principal Investigator, 6%, Noninvasive vs Invasive Lung Evaluation Clinical Trial, PA16-0590, Guardant Health, 9/15/2016-9/14/2018, $68,764 ($68,764/year) Principal Investigator, 2%, A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies, Nektar Therapeutics, 9/25/2017-10/4/2021 ($10,000/year) Principal Investigator, BATTLE immunotherapy: A randomized, phase 2 trial of trametinib in combination with MKL-3475 anti-PD-1 antibody versus MK-3475 Ant-PD-1 antibody in subjects with advanced, refractory to frontline chemotherapy non-small cell lung cancer, Award ID 54260, Novartis, 10/12/2017-12/31/2021 Principal Investigator, 3%, An open-label phase 1/2 study in INCB039110 in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer, Incyte Corporation, 11/14/2017-11/13/2020 Principal Investigator, 2%, A Multicenter, Two-Part, Phase 1b Clinical Study of CMP-001 in Combination with Atezolizumab with and without Radiation Therapy in Subjects with Advanced NSCLC, Checkmate Pharmaceuticals, 2/21/2018-2/20/2021 ($50,372/year) Principal Investigator, 2%, 2017-0891: A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects with Previously Treated Advanced EGFRm NSCLC, Medimmune, 3/1/2018-2/28/2021 ($32,275/year) Co-Investigator, 4%, Integrating tumor kinetics/radiomics in a master biomarker trial for lung cancer, U01-CA225431, Columbia University Medical Center/NCI, PI - Lawrence Schwartz, 6/1/2018-5/31/2023 ($9,934/year)

Pending Principal Investigator, Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer, CA225431-01, NIH/NCI

Other N/A

Completed Principal Investigator, Young Investigator Award: Effects of Biochemoprevention on Cell Cycle Regulator Abnormalities During Head and Neck Tumorigenesis, American Society of Clinical Oncology (ASCO), 1998, $35,000 Co-Principal Investigator, Biochemoprevention Therapy in Advanced Laryngeal Dysplasia, CA79437-03, NIH/NCI, PI - Waun Ki Hong, 9/10/1998-6/30/2004, $441,815 ($88,363/year) Principal Investigator, Randomized, Double-Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia, CA70907, NIH/NCI, 1/31/2000-1/31/2001, $107,023 Co-Investigator, Clinical and Epidemiologic Center for Biomarkers of Upper Aerodigestive Tract Lesions, CA86390, NIH/NIBIB, 5/1/2000-2/28/2005, $123,267 ($24,653/year) Principal Investigator, Alterations of Cell Cycle Regulators and their Signaling Partners as Predictors of Response to Chemoprevention and Cancer Risk in Upper Aerodigestive Tract


Page 6 of 47

Premalignancy, American Society of Clinical Oncology (ASCO), 7/1/2000-6/30/2003, $56,700 ($18,900/year) Principal Investigator Developmental Research Project, Multitargeted Therapy Aiming at Signal Transduction Pathways in Head and Neck Cancer, Department of Defense (DOD), PI - Hong WK, 3/15/2001-3/15/2009, $62,500 Principal Investigator, Project 4: SPORE in Head and Neck Cancer - Targeting EGFR for Chemoprevention of Head & Neck Cancers, P50 CA97007-01, NIH/NCI, 8/1/2001-6/30/2006, $211,391 Co-Investigator, 10%, MDACC SPORE in Head and Neck Cancer, 3P50 CA97007 08, NIH/NCI (PP-3B), PI - Scott Lippman, 7/1/2002-7/31/2013 ($1,493,507/year) Principal Investigator, Development Project, Multitargeted therapy aiming at signal transduction pathways in head and neck cancer, P50 CA97007-02, NIH/NCI, 9/30/2002-7/31/2007, $47,509 ($47,509/year) Project 3 Co-Leader, 10%, MD Anderson Cancer Center Head and Neck SPORE (PP-3), CA106451-06, NIH/NCI, PI - Jeffrey Myers, 9/30/2002-7/31/2013, $1,493,507 Project 1 Leader, 10%, Molecular-Based Therapy for Oral Cancer Prevention, 5 P01 CA106451 06, NIH/NCI, PI - Scott Lippman, M.D., 8/1/2004-7/31/2012 Co-Investigator, 1%, Early Therapeutic Development with Phase II Emphasis, N01 CM-62202 09, NIH/NCI, PI - David J Stewart, 1/1/2006-9/30/2011 ($8,317,052/year) Co-PI, BATTLE Lung Cancer Program, W81XWH-06-1-0303, Department of Defense, PI - Hong, 4/1/2006-4/30/2011 Principal Investigator, 7%, A Biomarker-Integrated Study in previously treated patients with Non-Small Cell Lung Cancer, CS2011-000333934LG 01, Merck and Company, 12/10/2010-12/31/2016, $4,960,882 Co-Principal Investigator, 15%, Personalizing NSCLC Therapy: Exploiting KRAS activated pathways, R01 CA155196-01A1, NIH/NCI, PI - Roy Herbst, 9/15/2011-7/31/2017 ($514,442/year) Principal Investigator, 1%, Whole transcriptome sequencing in specimens obtained from patients with refractory NSCLC receiving therapy as part of the BATTLE-2 Program, MD Anderson Cancer Center, 4/29/2013-2/28/2019 ($200,125/year) Principal Investigator, 1%, Biomarkers from a Randomized Phase II Trial Contrasting Weekly Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma, Bristol - Myers Squibb, 7/18/2013-7/17/2018 ($481,440/year) Collaborator, 3%, Next Generation Sequencing and Transcriptome Profiling of Oral Potentially Malignant Lesions to Identify Markers of Cancer Risk and Targets Chemoprevention, Cancer Prevention & Research Institute of Texas (CPRIT), PI - William Nassib William MD, 8/31/2014-8/30/2017, $614,146 ($285,000/year) Principal Investigator, 4%, A Phase I/II, Multicenter, Open Label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-Type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients with Previously Treated EGFR mut and Acquired T790M Mutation Non-Small Cell Lung Cancer, ACEA Biosciences, 3/1/2015-2/28/2018, $242,354 Co-Principal Investigator, 10%, Personalizing NSCLC Therapy: Targeting immune escape and MEK pathways, Yale University/NIH/NCI Subaward, PI - Roy Herbst, 4/1/2017-3/31/2022, $1,350,000 ($270,000/year)

Not Funded N/A

Protocols


Page 7 of 47

Funded Principal Investigator, Induction biochemoprevention followed by fenretinide versus placebo maintenance for laryngeal dysplasia, ID98-017, 1998, NCI Principal Investigator, Randomized, double blind, placebo-controlled, phase IIB trial of ketorolac mouth rinse evaluating the effect of cyclooxygenase inhibition on oropharyngeal leukoplakia: collaborative study of the NCI, NIDCD and the NIDR, ID99-302, 1999 Principal Investigator, Phase IIB Double-Blind, Placebo-Controlled, Randomized Study of Celecoxib on Oral Premalignant Lesions, SC-58635, 2001-2002, Searle Principal Investigator, Phase II study of TLK286 administered weekly in advanced non-small cell lung cancer, ID02-225, 2002, Telik Principal Investigator, Phase I-II Study of the EGFR TKI EKB-569 in Combination with the MTOR Inhibitor CCI-779 in Patients with Advanced and Refractory to Conventional Chemotherapy NSCLC, 2003-0918, 2003, Wyeth Principal Investigator, A Phase Ib Study of RAD001 in Combination With Gemcitabine, Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Advanced Solid Tumors, 2004-0275, 2004, Novartis Principal Investigator, Early Detection of Recurrence in Non-Small Cell Lung Cancer Patients, LAB04-0130, 2004, Immunicon Principal Investigator, A Phase II Evaluation of Bevacizumab (Avastin) in Combin, 2005-0224, 2005-2016, $260,024, Genentech, Inc. Principal Investigator, A phase IB study investigating the combination of RAD001 with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer not previously treated with chemotherapy, CS2007-00019078RG, 2006-2011, $87,753, Novartis Principal Investigator, An Open Label, Multi-Center, Phase I Study To Assess The Maximum Tolerated Dose of ZD6474 (ZACTIMA) Given Concomitantly with Radiation Therapy or Concomitantly with Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients with Previously Untreated, Unresected, Stage III-IV Head and Neck Squamous Cell Carcinoma., 2006-0492, 2006-2012, AstraZeneca Principal Investigator, Erlotinib prevention of oral cancer (EPOC), 2003-0824, 2006, NCI and OSI Pharmaceuticals Principal Investigator, Phase II Clinical Trial of the Combination of RAD001 and Erlotinib in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck, CS2009-00026564EB 01, 2009-2013 ($80,309/year), Novartis, OSI Principal Investigator, BATTLE-2 Program: Biomarker-Integrated Study in Chemorefractory Patients with Advanced NSCLC (BATTLE-2), CS2011-000344795LG 01, 2011-2015 ($3,229,148/year), Merck & Company, Bayer Corporation, OSI, AstraZeneca Principal Investigator, Phase 3, randomized, open label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus, CS2011-000033803JW 01, 2011-2016, $56,907, Pfizer Pharmaceuticals Co-Chair, A Phase I, Open-Label Multicenter, Dose Escalation, Multidose Study of BMS-93559(MDX-1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors, BMS-936559 - 2011-0434, 2011 ($144,090/year), Bristol-Myers Squibb Principal Investigator, An open label phase I study to assess safety tolerability, PK and preliminary anti-tumor activity of ascending doses of AZD447 in patients with advanced solid malignancies, AZD4547, 2011, AstraZeneca


Page 8 of 47

Principal Investigator, Phase II ERCC1 and RRM1-based adjuvant therapy trial in patients with stage I non-small cell lung cancer (NSCLC), SWOGS0720, 2011, Southwest Oncology Group (SWOG) Principal Investigator, A Phase I/II, open label, safety, PK and preliminary efficacy study of oral CO-1686 in patients with previously treated mutant EGFR NSCLC, 2012-0009, 2012-2013, Clovis Principal Investigator, An open label Phase I study to assess safety, tolerability, PK and preliminary anti-tumor activity of ascending doses of AZD4547 in patients with advanced solid malignancies, CS2012-00036466RG 01, 2012-2015 ($309,651/year), AstraZeneca Principal Investigator, A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced/Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma, CA186-107, 2012, Bristol-Myers Squibb Principal Investigator, Molecular profiling of NSCLC to determine mechanisms of resistance to therapy, PA12-0154, 2012, MDACC Principal Investigator, Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination with Erlotinib or Oral Azacytidine in Advanced Non - Small Cell Lung Cancer, CC-223-NSCL-001, 2013-2015, $174,543, Celgene Principal Investigator, TIGER 1: A Randomized, Open Label, Phase II Study of CO-1686 or Erlotinib as First - Line Treatment of Patients with EGFR - Mutant Advanced Non-Small Cell Lung Cancer (NSCLC), 2014 - 0803, 2014-2017, Clovis Oncology Principal Investigator, A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma, 2013-0551, 2014, Janssen Principal Investigator, A Phase 1B Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer, 2014-0109, 2014, Medimmune Principal Investigator, A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma, 2013-0984, 2014, Merck Study Chairman, A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer, 2013-0691, 2014, Merck Principal Investigator, Phase I/II Trial of Ipilimumab (Immunotherapy) and Hypofractionated Stereotactic Radiation Therapy in Patients with Advanced Solid Malignancies, 2013-0882, 2014, Bristol Myers Squibb Principal Investigator, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer, SWOG S1400, 2014, Amgen, AstraZeneca, Genentech, Medimmune, NCI, Pfizer Principal Investigator, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer. Study A: MEDI4736; Study B: GDC-0032; Study C: Palbociclib; Study D: AZD4547; Study E: Rilotumumab + Erlotinib, SWOGS1400, 2014 Principal Investigator, A Phase I/II, Multicenter, Open Label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-Type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients with Previously Treated EGFR mut and Acquired T790M Mutation Non-Small Cell Lung Cancer, 2014-0863, 2015-2018, $242,354, ACEA Biosciences Principal Investigator, A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination with Carboplatin +


Page 9 of 47

NAB-Paclitaxel for Chemotherapy -Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer, 2015-0559, PI - Papadimitrakopoulou, 2015-2018, $658,068, Genentech Principal Investigator, A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer, 2015-0194, PI - Papadimitrakopoulou, 2015-2020, $355,094, BMS/Novartis Principal Investigator, An open-label phase 1 study of safety and immunogenicity of JNJ-64041757, a live attenuated listeria monocytogenes immunotherapy, in subjects with non-small cell lung cancer, 2015-0873, PI - Papadimitrakopoulou, 2016-2018, $209,214, Janssen Principal Investigator, Noninvasive vs Invasive Lung Evaluation Clinical Trial, PA16-0590, 2016-2018, $68,764, Guardant Health Principal Investigator, An Open-Label, Phase I Study of the Safety and Immunogen, 2016-, 2016-2019, $238,845, Janssen Research and Development Principal Investigator, An open-label phase 1/2 study in INCB039110 in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer, 2017-0331, 2017-2018, Incyte Corporation Principal Investigator, BATTLE immunotherapy: A randomized, phase 2 trial of trametinib in combination with MKL-3475 anti-PD-1 antibody versus MK-3475 Ant-PD-1 antibody in subjects with advanced, refractory to frontline chemotherapy non-small cell lung cancer, 2017-0226, 2017-2021, Novartis

Unfunded Principal Investigator, Phase II Study of Induction Intra-Arterial Cisplatin in Combination with Intravenous Taxol and Ifosfamide in Patients with Paranasal Sinus Tumors, ID98-015, 1998, Bristol Myers Squibb Principal Investigator, A Pilot Study of Adenovirus Onyx-015 Administered by Mouthwash as a Chemopreventive Agent and for the Treatment of Oral Dysplastic Lesions, HN599-140, 1999, Onyx Pharmaceuticals Collaborator, A Phase I, Open-Label, Dose-Escalating Study to Evaluate the Biological Activity and Pharmacokinetics of PKI166 in Patients with Advanced Cancers Accessible for Biopsy, DM99-385, 2000, Novartis Principal Investigator, Phase I/II Study of RO31-7453, A Novel Cell Cycle Inhibitor, Administered in Combination with I.V. Paclitaxel In Adults With Solid Tumors, and At MTD in First Line NSCLC, DM00-130, 2000 ($241,231/year), Hoffman LaRoche Principal Investigator, Phase II Study of TLK286 for the Treatment of Advanced Non-small Cell Lung Cancer Patients Who Have Failed First-line Therapies with Platinum-containing Regimen, CS01-247-1, 2001-2002 Principal Investigator, A Phase II Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Pilot Study of Orally Administered Green Tea Extract for the Chemoprevention of Malignant Progression of Oral Premalignant Lesions in High Risk Patients., ID01-155, 2002, $255,655, ITO-EN Principal Investigator, Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer, DM02-396, 2003 ($25,565,551/year), Telik Collaborator, Phase I & II Clinical Trials of Chemopreventive Agents, N01CN-035159 04, 2003, NCI Principal Investigator, Phase I/IIA dose-ranging study of TLK286 in combination with Cisplatin as first-line therapy in locally-advanced or metastatic non-small cell lung cancer, 2003-0703, 2003, Telik


Page 10 of 47

Principal Investigator, A Combined Phase I and 2 Study Investigating the Combination of RAD001 and Erlotinib in Patients With Advanced NSCLC Previously Treated Only With Chemotherapy, 2004-0937, 2004 ($9,327,648/year), Novartis Co-Principal Investigator, A Phase II Study of ZD6474 Alone and with Chemotherapy in Advanced NSCLC, 2003-0635, 2004 ($9,111,400/year), NCI Principal Investigator, A Multiple Dose, Open Label Phase IB Trial to Determine Safety and Pharmacokinetics of Escalating Doses of Intravenously Administered (IV) CGP 48664 in Combination with Cisplatin and 5-Fluorouracil in Squamous Cell Head and Neck Cancer Patients, DM98-164, 2005, Novartis Collaborator, Evaluation of OraTest in combination with visual examination in the improved detection of oral mucosal lesions suspicious of serious pathology in high-risk patients for the purpose of referral to the health care professional experienced in oral cancer: Phase III clinical trial comparing the sensitivity and assessing the specificity of OraTest in combination with visual examination and visual examination alone in patients at high risk as defined by age and lifestyle factors (ZIL-401), 2005-1008, 2005, Zila Biotechnology Principal Investigator, Multiple Ascending Dose (MAD) Phase I Study of the CDK Inhibitor RO4584820 Administered as an Intravenous Infusion on a Weekly Schedule in Patients with Advanced Solid Tumors, 2005-0130, 2005 ($268,187/year), Hoffman-La Roche Principal Investigator, Open Label, Non Randomized, Phase 2 Study Investigating The Effect of RAD001 Monotherapy In Patients With Advanced NSCLC previously Treated With Either Chemotherapy Only or With Chemotherapy and EGFR Inhibitor(s), 2005-0408, 2005 ($167,068/year), Novartis Principal Investigator, Phase 3 Randomized Study of TLK286 (Telcyta) versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer, 2005-0065, 2005, $129,767, Telik Principal Investigator, Roche sample repository research project in association with protocol NP183778, LAB 05-0254, 2005, Hoffman La Roche Principal Investigator, A two-step phase study investigating the combination of RAD001 with Carboplatin, Paclitaxel and Bevacizumab in non-small cell lung cancer (NSCLC) patients non treated previously with systemic therapy, 2006-0894, 2006, Novartis Principal Investigator, Phase II study of Dasatinib in the treatment of Head and Neck Squamous Cell Carcinoma., 2006-0571, 2006, NCI/CTEP Principal Investigator, Phase IIA trial of rosiglitazone (Avandia) for oral leukoplakia, 2005-0485, 2006, NCI Principal Investigator, A phase I dose-escalation, multicenter, open label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including Phase II expansion arms in patients with either HER2 positive or ER positive locally advanced of metastatic breast cancer (CAUY922A2101), 2007-0927, 2007, Novartis Principal Investigator, A Phase I Study to Determine The Safety and Pharmacokinetics of BMS-387032 Given Every Three Weeks In Patients With Metastatic Refractory Solid Tumors, ID01-326, 2007, Bristol Myers Squibb Principal Investigator, A phase IB, open-label, multicenter study to investigate the effect of oral LBH589 on detromethorphan, a CYP2D6 substrate, and to assess the efficacy and safety of oral LBH589 in patients with advanced or metastatic non-small cell lung cancer or malignant pleural mesothelioma, 2007-0644, 2007, Novartis Principal Investigator, Randomized Phase II trial contrasting weekly paclitaxel, carboplatin and cetuximab (PCC) with cetuximab, docetaxel, cisplatin and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma, 2009-0885, 2014, MD Anderson Cancer Center


Page 11 of 47

Principal Investigator, A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer, 2014-0109, 2015-present, Medimmune

Patents and Technology Licenses Patents

N/A Technology Licenses

N/A

Grant Reviewer/Service on Study Sections Study Section Review Committee for Clinical Translational and Population Based Research Projects under the Institutional Research Grants Program (IRG), MD Anderson Cancer Center, Member, 2014-2017 2015 AACR Princess Takamatsu Memorial Lectureship, American Association for Cancer Research (AACR), Member, 2014 AACR Clinical and Translational Cancer Research Grants Scientific Review Committee, American Association for Cancer Research (AACR), Member, 2015-present AACR Lung Cancer Research Grants Scientific Review Committee, American Association for Cancer Research, Member, 2016-2018 ASCO University Review Panel Member, ASCO, Member, 2017-present Reviewer Israeli Ministry of Science, Technology and Space- RFP-Personalized Medicine, Ministry of Science, Technology and Space, Reviewer, 2017-present

PUBLICATIONS Peer-Reviewed Original Research Articles

1. Cvitkovic FB, Haie-Meder C, Papadimitrakopoulou V, Armand JP, Cioloca C, Maugis N, Constans JP. Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. J Neurooncol 15(1):9-17, 1/1993. PMID: 8384255.

2. Kim SK, Fan Y, Papadimitrakopoulou V, Clayman G, Hittelman WN, Hong WK, Lotan R, Mao L. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 56(11):2519-21, 6/1996. PMID: 8653689.

3. Sarris AH, Luthra R, Papadimitrakopoulou V, Kimopoulos M, McBride JA, Cabanillas F, Morris S, Deisseroth A, Pugh WC. Amplification of genomic DNA-PCR technique demonstrates the presence of the t (2; 5) rearrangement in anaplastic large cell lymphoma but no other non-Hodgkin's lymphomas; Hodgkin's disease or lymphomatoid papulosis. Blood 88:1771-1779, 1996.

4. Papadimitrakopoulou VA, Hong WK, Lee JS, Martin JW, Lee JJ, Batsakis JG, Lippman SM. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 89(3):257-8, 2/1997. PMID: 9017007.

5. Papadimitrakopoulou VA, Dimery IW, Lee JJ, Perez C, Hong WK, Lippman SM. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Cancer J Sci Am 3(2):92-9, Mar-Apr, 3/1997. PMID: 9099459.

6. Papadimitrakopoulou V, Izzo J, Lippman SM, Lee JS, Fan YH, Clayman G, Ro JY, Hittelman WN, Lotan R, Hong WK, Mao L. Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 14(15):1799-803, 4/1997. PMID: 9150385.

7. Sarris AH, Papadimitrakopoulou V, Dimopoulos MA, Smith T, Pugh W, Ha CS, McLaughlin P, Callender D, Cox J, Cabanillas F. Primary parotid lymphoma: the effect of International Prognostic Index on outcome. Leuk Lymphoma 26(1-2):49-56, 6/1997. PMID: 9250787.

8. Sarris AH, Papadimitrakopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Ann Oncology 8:S59-S63, 1997.


Page 12 of 47

9. Sarris AH, Luthra R, Papadimitrakopoulou V, Waasdorp M, Dimopoulos M, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris S, Pugh WC. Rapid amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Ann Oncology 8 (Suppl 2):S1-S5, 1997.

10. Papadimitrakopoulou VA, Oh Y, El-Naggar A, Izzo J, Clayman G, Mao L. Presence of multiple in contiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. Clin Cancer Res 4(3):539-44, 3/1998. PMID: 9533520.

11. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, Lawhorn K, Gillenwater AM, Ang KK, Clayman GL, Callender DL, Hong WK, Lippman SM. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 16(4):1325-30, 4/1998. PMID: 9552033.

12. Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS, Hittelman WN, Lippman SM, Hong WK. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 90(20):1545-51, 10/1998. PMID: 9790547.

13. Izzo JG, Papadimitrakopoulou VA, Li XQ, Ibarguen H, Lee JS, Ro JY, El-Naggar A, Hong WK, Hittelman WN. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene 17(18):2313-22, 11/1998. PMID: 9811462.

14. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS, Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 125(10):1083-9, 10/1999. PMID: 10522499.

15. Shin DM, Mao L, Papadimitrakopoulou VM, Clayman G, El-Naggar A, Shin HJ, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst 92(1):69-73, 1/2000. PMID: 10620636.

16. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 6(5):1702-10, 5/2000. PMID: 10815888.

17. Soria JC, Izzo J, Mao L, Hong WK, Papadimitrakopoulou VA. [Biomarkers of carcinogenesis of the upper and lower airway epithelium and the role of chemoprevention]. Bull Cancer 88(4):351-61, 4/2001. PMID: 11371369.

18. Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91(7):1316-23, 4/2001. PMID: 11283932.

19. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers J, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goepfert H, Hong WK. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19(12):3010-7, 6/2001. PMID: 11408495.

20. Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, Shin DM, El-Naggar A, den Hollander P, Liu D, Hittelman WN, Hong WK. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 7(10):3127-34, 10/2001. PMID: 11595705.

21. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12(1 Suppl 1):46-9, 1/2002. PMID: 11917284.

22. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M,


Page 13 of 47

Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8(2):314-46, 2/2002. PMID: 11839647.

23. Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95(2):322-30, 7/2002. PMID: 12124833.

24. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 95(2):340-53, 7/2002. PMID: 12124835.

25. Papadimitrakopoulou VA, Liu DD, Mao L, Shin DM, El-Naggar A, Ibarguen H, Lee JJ, Hong WK, Hittelman WN. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev 11(12):1605-10, 12/2002. PMID: 12496051.

26. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101, 1/2003. PMID: 12538456.

27. Izzo JG, Papadimitrakopoulou VA, Liu DD, den Hollander PL, Babenko IM, Keck J, El-Naggar AK, Shin DM, Lee JJ, Hong WK, Hittelman WN. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 95(3):198-205, 2/2003. PMID: 12569141.

28. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park) 17(7 Suppl 7):17-21, 7/2003. PMID: 12886869.

29. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer 5(1):40-5, 7/2003. PMID: 14596703.

30. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM, Clayman G, Morrison WH, Liu DD, Blumenschein G, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer 98(10):2214-23, 11/2003. PMID: 14601092.

31. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21(24):4546-52, 12/2003. e-Pub 11/2003. PMID: 14597742.

32. Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer 100(5):991-8, 3/2004. PMID: 14983495.

33. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman SM, Frye R, Cavanaugh PF. Randomized, double-blind, placebo-controlled phase IIb trial of the


Page 14 of 47

cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 10(5):1565-73, 3/2004. PMID: 15014005.

34. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369-77, 4/2004. PMID: 15050312.

35. Tran HT, Blumenschein GR Jr, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Troung M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54:308-15, 2004. PMID: 15184994.

36. Mao L, Hong WK, Papadimitrakopoulou V. Focus on head and neck cancer. Cancer Cell 5:311-6, 2004.

37. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 10:2968-76, 2004. PMID: 15131032.

38. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou V, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 10:658-67, 2004. PMID: 14760089.

39. Glover K, Perez-Soler R, Papadimitrakopoulou V. Tynsive Kinase inhibitors in development for non-small cell lung cancer. Sem in Oncology 31:83-92, 2004.

40. Massarelli E, Brown E, Tran NK, Liu DD, Izzo JG, Lee JJ, El-Naggar AK, Hong WK, Papadimitrakopoulou VA. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer 103(5):952-9, 3/2005. PMID: 15666322.

41. Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 63(3):717-24, 11/2005. PMID: 16199307.

42. Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104(11):2430-6, 12/2005. PMID: 16245318.

43. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer. Cancer 104 (11)(11):2449-56, 12/2005. PMID: 16258975.

44. Papadimitrakopoulou V, Agelaki S, Tran HT, Kies M, Gagel R, Zinner R, Kim E, Ayers G, Wright J, Khuri F. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. Clin Cancer Res 11:4151-9, 2005. PMID: 15930851.

45. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V,. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant non-small cell lung carcinoma. Cancer 104:561-9, 2005.

46. Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou VA, Huang S, Hong WK. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 11 (16):6065-74, 2005.

47. Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong


Page 15 of 47

WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 12(10):3109-14, 5/2006. PMID: 16707609.

48. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 6/2006. PMID: 16778094.

49. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):441S-445S, 7/2006. PMID: 16857825.

50. Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Jack Lee J, Hong WK, Lee HY. The Prognostic Role of Loss of Insulin-like Growth Factor-binding Protein-3 Expression in Head and Neck Carcinogenesis. Cancer Lett 239(1):136-43, 7/2006. e-Pub 9/2005. PMID: 16181731.

51. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24(25):4163-9, 9/2006. PMID: 16943532.

52. Papadimitrakopoulou V, Adjei AA. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J Thorac Oncol 1(7):749-51, 9/2006. PMID: 17409953.

53. Kelloff GJ. Lippman SM. Dannenberg AJ. Sigman CC. Pearce HL. Reid BJ. Szabo E. Jordan VC. Spitz MR. Mills GB. Papadimitrakopoulou VA. Lotan R. Aggarwal BB. Bresalier RS. Kim J. Arun B. Lu KH. Thomas ME. Rhodes HE. Brewer MA. Follen M. Shin DM. Parnes HL. Siegfried JM. Evans AA. Blot WJ. Chow WH. Blount PL. Maley CC. Wang KK. Lam S. Lee JJ. Dubinett SM. Engstrom PF. Meyskens FL Jr. O'Shaughnessy J. Hawk ET. Levin B. Nelson WG. Hong WK. AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12 (12):3661-97, 2006.

54. Lippman SM. Lee JJ. Martin JW. El-Naggar AK. Xu X. Shin DM. Thomas M. Mao L. Fritsche HA Jr. Zhou X. Papadimitrakopoulou V. Khuri FR. Tran H. Clayman GL. Hittelman WN. Hong WK. Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. [Clinical Trial, Phase II. Research Support, N.I.H., Extramural]. Clin Cancer Res 12:3109-14, 2006.

55. Gillenwater A. Papadimitrakopoulou V. Richards-Kortum R. Oral premalignancy: new methods of detection and treatment. Curr Oncol Reports:146-54, 2006.

56. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Patients with locally Advanced Squamous Cell Cancer of the Head and Neck. J Clin Oncol 24:4163-9, 2006.

57. Papadimitrakopoulou V, Adjei AA. The Akt/mTOR and MAP Kinase Pathways in Lung Cancer Therapy. J Thor Oncol 1 (7):749-51, 2006.

58. Bristol IJ, Ahamad A, Garden AS, Morrison WH, Hanna EY, Papadimitrakopoulou VA, Rosenthal DI, Ang KK. Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys 68(3):719-30, 7/2007. PMID: 17543999.

59. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry


Page 16 of 47

WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 3(1):1-33, 2007.

60. Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26(1):81-7, 2/2008. e-Pub 10/2007. PMID: 17960324.

61. O'Donnell A, Faivre S, Burris HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26(10):1588-95, 4/2008. e-Pub 3/2008. PMID: 18332470.

62. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized Phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14(7):2095-101, 4/2008. PMID: 18381950.

63. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin: A novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-60, 2008.

64. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila Pa) 2(1):14-21, 1/2009. PMID: 19139013.

65. William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High dose Fenretinide in oral leukoplakia. Cancer Prev Res (Phila Pa) 2(1):22-6, 1/2009. PMID: 19139014.

66. Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27(4):599-604, 2/2009. e-Pub 12/2008. PMCID: PMC2645856.

67. Saba NF, Choi M, Muller S, Shin HJ, Tighiouart M, Papadimitrakopoulou VA, El-Naggar AK, Khuri FR, Chen ZG, Shin DM. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila Pa) 2(9):823-9, 9/2009. e-Pub 9/2009. PMCID: PMC2910364.

68. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer inpatients with leukoplakia. Clin Cancer Res 15(19):6284-91, 10/2009. e-Pub 9/2009. PMCID: PMC2756317.

69. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V. Efficacy of Everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 20(10):1674-91, 10/2009. e-Pub 6/2009. PMID: 19549709.

70. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila Pa) 2(11):931-41, 11/2009. PMID: 19892663.

71. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results from a Phase II prospective trial. J Clin Oncol 28(1):8-14, 1/2010. e-Pub 11/2009. PMCID: PMC2799235.

72. Yildirim G, Morrison WH, Rosenthal DI, Sturgis EM, Papadimitrakopoulou VA, Schwartz DL, Garden AS. Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy. Head Neck 32(4):473-80, 4/2010. e-Pub 8/2009. PMID: 19691110.


Page 17 of 47

73. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-63, 6/2010. e-Pub 6/2010. PMCID: PMC2913168.

74. Benchekroun MT, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila Pa) 3(7):800-9, 7/2010. e-Pub 6/2010. PMCID: PMC2900459.

75. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 5(11):e14124, 2010. e-Pub 11/2010. PMCID: PMC2993951.

76. Guo M, Sneige N, Patel S, Feng J, Papadimitrakopoulou V, Sturgis E, Etzel Z, Hong WK, Tsao A. HPV infection and oral cytological changes in patients with oropharyngeal squamous carcinoma and their sexual partners. Cancer Cytopath 118(5):349-50, 2010.

77. Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L. Gene expression rofiling predicts the development of oral cancer. Cancer Prev Res (Phila) 4(2):218-29, 2/2011. PMCID: PMC3074595.

78. Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN. Vandetanib restores head and neck squamous cell carcinoma cell's sensitivity to Cisplatin and radiation in vivo ad in vitro. Clin Cancer Res 17(7):1815-27, 4/2011. e-Pub 2/2011. PMCID: PMC3074405.

79. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117(10):2112-9, 5/2011. e-Pub 11/2010. PMCID: PMC3117018.

80. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 29(3):499-505, 6/2011. e-Pub 1/2010. PMID: 20094773.

81. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing therapy for lung cancer. Cancer Discov 1(1):44-53, 6/2011. e-Pub 6/2011. PMCID: PMC4211116.

82. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trial of Imatinib Mesylate and Docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 6(12):2104-11, 12/2011. e-Pub 9/2011. PMID: 21892101.

83. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: Implications for signaling and clinical outcome. J Natl Cancer Inst 104(3):228-39, 2/2012. e-Pub 1/2012. PMCID: PMC3274509.

84. Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small cell lung cancer. J Thorac Oncol 7(8):1315-26, 8/2012. e-Pub 5/2012. PMID: 22648207.

85. Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small cell lung cancer: A phase I trial. J Thorac Oncol 7(10):1594-601, 10/2012. PMID: 22968184.


Page 18 of 47

86. Massarelli E, Papadimitrakopoulou VA. Phosphatidykinosital 3-kinase and Mammalian target of rapamycin pathway in non-small-cell lung cancer. J Thorac Oncol 7(16 Suppl 5):S379-82, 12/2012. PMID: 23160325.

87. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DS, Vaporciyan AA, Wistuba II, Swisher SG; University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 7(5):825-32, 2012. PMCID: PMCPMC3465940.

88. Papadimitrakopoulou V. Secondary therapeutic strategies for EGF receptor pathway inhibition in non-small cell lung cancer. Forum Clin Oncol 3(Spec Issue):45-50, 2012.

89. William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 8(2):222-8, 2/2013. e-Pub 1/2013. PMCID: PMC3549050.

90. Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer 80(3):235-41, 6/2013. e-Pub 2/2013. PMID: 23485129.

91. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S, Banerji U. First-in-human phase I dose escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 19(13):3671-3680, 7/2013. e-Pub 6/2013. PMID: 23757357.

92. Tsao AS, Papadimitrakopoulou V. The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Non-Small-Cell Lung Cancer: Focus on Clinical Trial Results. Clin Lung Cancer 14(4):311-21, 7/2013. e-Pub 4/2013. PMID: 23582282.

93. Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):139-47, 9/2013. PMID: 23920393.

94. Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG, Heymach JV, Blumenschein G, Cox JD, Hofstetter W, Fang B, Fossella F, Glisson B, Hong WK, Gold K, Johnson F, Kies MS, Liao Z, Lin S,. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncology 15(1):e42-50, 1/2014.

95. Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N, Dimitrijevic S, Urva S, Pylvaenaeinen I, Petrovic K, Johnson BE. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Ann Oncol 25(2):505-11, 2/2014. e-Pub 12/2013. PMID: 24368401.

96. Eberhardt WE, Mitchell P, Schiller JH, Brown MP, Thomas M, Mills G, Jehl V, Urva SR, De Leo JJ, Gogov S, Papadimitrakopoulou V. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. Invest New Drugs 32(1):123-34, 2/2014. e-Pub 4/2013. PMID: 23579358.

97. Besse B, Leighl N, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, Soria JC, Gogov S, Miller N, Jehl V, Johnson BE. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol 25(2):409-15, 2/2014. e-Pub 12/2013. PMID: 24368400.

98. Hutcheson KA, Lewin JS, Holsinger FC, Steinhaus G, Lisec A, Barringer DA, Lin HY, Villalobos S, Garden AS, Papadimitrakopoulou V, Kies MS. Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally


Page 19 of 47

advanced squamous cell carcinoma of the head and neck. Head Neck 36(4):474-80, 4/2014. e-Pub 6/2013. PMCID: PMC4034517.

99. Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. e-Pub 10/2014. PMCID: PMC4414661.

100. Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck 36(11):1547-54, 11/2014. e-Pub 3/2014. PMCID: PMC4010580.

101. Dimou A, Papadimitrakopoulou V. Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. J Pers Med 4(3):386-401, 2014. e-Pub 6/2014. PMCID: PMC4263964.

102. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS. Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK. Clin Cancer Res 21(4):739-48, 2/2015. e-Pub 12/2014. PMCID: PMC4335074.

103. Massarelli E, Papadimitrakopoulou V. Ceritinib for the Treatment of Late-Stage (Metastatic) Non-Small Cell Lung Cancer. Clin Cancer Res 21(4):670-4, 2/2015. e-Pub 1/2015. PMID: 25564153.

104. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res 21(7):1514-24, 4/2015. e-Pub 2/2015. PMID: 25680375.

105. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 372(18):1700-9, 4/2015. PMID: 25923550.

106. Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. Innovative Clinical Trials: The LUNG-MAP Study. Clin Pharmacol Ther 97(5):488-91, 5/2015. e-Pub 2/2015. PMID: 25676724.

107. Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 26(7):1476-80, 7/2015. e-Pub 5/2015. PMID: 26025965.

108. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5(8):860-77, 8/2015. e-Pub 6/2015. PMCID: PMC4527963.

109. Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP-framework, overview, and design principles. Chin Clin Oncol 4(3):36, 9/2015. PMID: 26408303.

110. Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. Statistics in Biosciences 7(2):1-30, 10/2015.


Page 20 of 47

111. William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncology:1-8, 2015 Nov 5, 11/2015. PMID: 26540028.

112. Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Mitchell FT, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar A, Lee JJ, Myers JN, Issa JJ, Lippman SM, Mao L, Saintigny P. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila), 2015. e-Pub 9/2015. PMID: 26342026.

113. Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD, Wistuba II. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. Cancer Res 76(3):675-85, 2/2016. e-Pub 12/2015. PMCID: PMC4738155.

114. Peters S, Antonia S, Goldberg SB, Heymach JV, Kim ES, Nakagawa K, Papadimitrakopoulou V, Mukhopadhyay P, McIntosh S, Rizvi NA. 191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. J Thorac Oncol 11(4 Suppl):S139-40, 4/2016. e-Pub 4/2016. PMID: 27198327.

115. Tsao A, Papadimitrakopoulou V, Lin H, Ming G, Lee JJ, Holsinger FC, Hong WK, Sturgis E. Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infectious Agents and Cancer, 4/2016. PMCID: PMCPMC4847345.

116. Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol 11(5):613-38, 5/2016. e-Pub 3/2016. PMID: 27013409.

117. Goepfert RP, Lewin JS, Barrow MP, Fuller CD, Beadle BM, Garden AS, Rosenthal DI, Kies MS, Papadimitrakopoulou V, Lai SY, Gross ND, Schwartz DL, Hutcheson KA. Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 6/2016. PMID: 27485284.

118. Aggarwal C, Langer C, Redman M, Hirsch F, Gandara D, Herbst R, Papadimitrakopoulou V. Targeted Therapy for Advanced Squamous Cell Lung Cancer. The Journal of Targeted Therapies in Cancer 5(3):49-54, 6/2016.

119. Lou Y, Diao L, Parra Cuentas E, Denning W, Chen L, Fan Y, Byers L, Wang J, Papadimitrakopoulou V, Behrens C, Wistuba I. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Research 22(14), 7/2016.

120. Goepfert R, Lewin J, Barrow M, Fuller GC, Lai S, Song J, Hobbs B, Gunn GB, Beadle B, Rosenthal D, Garden A, Kies M, Papadimitrakopoulou V, Schwartz D, Hutcheson K. Predicting Two-Year Longitudinal MD Anderson Dysphagia Inventory Outcomes after Intensity Modulated Radiotherapy for Locoregionally Advanced Oropharyngeal Carcinoma. Laryngoscope, 7/2016. PMID: 27440393.

121. Papadimitrakopoulou V, Lee JJ, Wistuba I, Tsao A, Fossella F, Kalhor N, Gupta A, Byers LA, Izzo J, Gettinger SN, Goldberg SM, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Diao L, Wang J, Wei C, Coombes KR, Koo JS, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE 2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with advanced Non-Small Cell Lung Cancer. Journal of Clinical Oncology, 8/2016. PMID: 27480147.


Page 21 of 47

122. Wagnar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Janne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. Journal of Thoracic Oncology 11(9):1387-1396, 9/2016. PMID: 27401214.

123. Gridelli C, Ascierto PA, Barberis MC, Felip E, Garon EB, O'brien M, Senan S, Casaluce F, Sgambato A, Papadimitrakopoulou V, De Marinis F. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Expert Opin Biol Ther:1-11. e-Pub 9/2016. PMID: 27650132.

124. Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer 99:79-87, 9/2016. e-Pub 6/2016. PMID: 27565919.

125. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L, KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. e-Pub 10/2016. PMID: 27745820.

126. Robles AI, Olsen KS, Tsui DW, Georgoulias V, Creaney J, Dobra K, Vyberg M, Minato N, Anders RA, Børresen-Dale AL, Zhou J, Sætrom P, Nielsen BS, Kirschner MB, Krokan HE, Papadimitrakopoulou V, Tsamardinos I, Røe OD. Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway. J Transl Med 14(1):295, 10/2016. e-Pub 10/2016. PMID: 27756323.

127. Jotte RM, Socinski MA, Reck M, Papadimitrakopoulou V, West HJ, Mok T, Sandler A, Mocci S, Coleman S, Asakawa T, Cappuzzo F. PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: Medical Oncology. J Thorac Oncol 11(11S):S302-S303, 11/2016. e-Pub 10/2016. PMID: 27969520.

128. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. e-Pub 12/2016. PMID: 27959700.

129. Tang H, Wang S, Xiao G, Schiller J, Papadimitrakopoulou V, Minna J, Wistuba II, Xie Y. Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies. Ann Oncol. e-Pub 2/2017. PMID: 28200038.

130. Mok TS, Wu YL, Papadimitrakopoulou VA. Osimertinib in EGFR T790M-Positive Lung Cancer. N Engl J Med 376(20):1993-4, 5/2017. PMID: 28514610.

131. Salem A, Bell D, Sepesi B, Papadimitrakopoulou V, El-Naggar A, Moran CA, Kalhor N. Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: The MD Anderson Cancer Center Experience and Comprehensive Review of the Literature. Virchows Arch., 6/2017.

132. Carter BW, Halpenny DF, Ginsberg MS, Papadimitrakopoulou VA, de Groot PM. Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. J Thorac Imaging 32(5):300-312, 9/2017. PMID: 28786858.

133. Shroff GS, Benveniste MF, de Groot PM, Wu CC, Viswanathan C, Papadimitrakopoulou VA, Truong MT. Targeted Therapy and Imaging Findings. J Thorac Imaging 32(5):313-322, 9/2017. PMID: 28832416.

134. Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG. JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol Cancer Ther 16(10):2234-2245, 10/2017. e-Pub 7/2017. PMCID: PMC5628136.

135. Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulou V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F.


Page 22 of 47

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. e-Pub 12/2017. PMID: 29396237.

136. Lam VK, Papadimitrakopoulou V. Master protocols in lung cancer: experience from Lung Master Protocol. Curr Opin Oncol 30(2):92-97, 3/2018. PMID: 29329112.

137. Saintigny P, William WN, Foy JP, Papadimitrakopoulou V, Lang W, Zhang L, Fan YH, Feng L, Kim ES, El-Naggar AK, Lee JJ, Mao L, Hong WK, Lingen MW, Lippman SM. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst 110(3), 3/2018. PMCID: PMC5946820.

138. Robichaux JP, Elamin Y, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson M, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach J. Structural features and clinical activity of an EGFR/HER2 exon 20-selective kinase inhibitor. Nature Medicine 24(5):638-646, 4/2018. e-Pub 4/2018.

139. Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24(5):638-646, 5/2018. e-Pub 4/2018. PMCID: PMC5964608.

140. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Jimenez Aguilar E, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery. e-Pub 5/2018. PMID: 29773717.

141. Shroff GS, de Groot PM, Papadimitrakopoulou VA, Truong MT, Carter BW. Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer. Radiol Clin North Am 56(3):485-495, 5/2018. PMID: 29622080.

142. Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. Clin Invest. e-Pub 5/2018.

143. Singh A, Ruiz C, Bhalla K, Haley JA, Li QK, Acquaah-Mensah G, Montal E, Sudini KR, Skoulidis F, Wistuba II, Papadimitrakopoulou V, Heymach JV, Boros LG, Gabrielson E, Carretero J, Wong KK, Haley JD, Biswal S, Girnun GD. De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer. FASEB J:fj201800204. e-Pub 6/2018. PMID: 29906244.

144. Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 128(6):2500-2518, 6/2018. e-Pub 5/2018. PMCID: PMC5983340.

145. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette J, Peng DH, Ungewiss C, Roybal JD, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, V Heymach J, Qin FX, Gibbons DL. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. e-Pub 7/2018. PMID: 30012853.


Page 23 of 47

146. Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol:JCO2018779363. e-Pub 7/2018. PMID: 30059262.

147. Lissanu Deribe Y, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, Khor T, Feng N, Lin YH, Wu CC, Reyes C, Peng Q, Robinson F, Inoue A, Kochat V, Liu CG, Asara JM, Moran C, Muller F, Wang J, Fang B, Papadimitrakopoulou V, Wistuba II, Rai K, Marszalek J, Futreal PA. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med 24(7):1047-1057, 7/2018. e-Pub 6/2018. PMID: 29892061.

148. Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer 6(1):75, 7/2018. e-Pub 7/2018. PMCID: PMC6048854.

149. Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Chih-Hsin Yang J, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller S, Gandhi L. 24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Thorac Oncol. e-Pub 8/2018. PMID: 30138764.

150. Sebastian M, Rydén A, Walding A, Papadimitrakopoulou V. Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. Lung Cancer 122:100-106, 8/2018. e-Pub 5/2018. PMID: 30032816.

151. Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok T. CNS efficacy of osimertinib in patients with T790M positive advanced NSCLC: data from a randomized Phase III trial (AURA3). Journal of Clinical Oncology. In Press.

152. Goldman JW, Karlovich C, Sequist LV, Melnikova V, Franovic A, Gadgeel S, Reckamp K, Camidge DR, Perol M, Ou I, Liu SV, Yu H, Soria JC, Socinski MA, Mekhail TM, Solomon BJ, Natale R, Otterson GA, Papadimitrakopoulou V, Langer C, Neal JW, Despain D, Yurasov S, Litten JB, Erlander M, Raponi M, Wakelee HA. EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Non-small Cell Lung Cancer Patients Treated with Rociletinib, an EGFR Tyrosine Kinase Inhibitor. J Clin Oncol Precision Oncology. In Press.

153. Tsao AS, Wistuba I, Xia D, Byers L, Diao L, Wang J, Papadimitrakopoulou V, Tang X, Lu W, Kadara H, Grigoryev D, Selvan ME, Gümüş ZH, Tan Z, Zhang S, Nilsson M, Heymach JV. Germline and somatic smoothened (SMO) mutations in non-small cell lung cancer (NSCLC) are potentially responsive to hedgehog inhibitor vismodegib. Journal of Precision Oncology. In Press.

154. Deribe YL, Sun Y, Khan F, Martinez-Ledesma E, Gay J, Feng N, Lin YH, Wu CC, Reyes C, Peng Q, Robinson F, Asara J, Moran C, Muller F, Marszalek J, Futreal PA, Liu CG, Terranova C, Mullinax R, Khor T, Gao G, Inoue A, Fang B, Kochat V, Wang J, Papadimitrakopoulou V, Wistuba II, Rai K. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med. In Press.

155. Tam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kalhor N, Kim ES, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks M, Hong WK, Gupta S. A Team-Science Approach to Support Personalized Cancer Care: Role and Value of Interventional Radiology in Clinical Trials. J Thorac Oncol. Submitted.

156. Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Byers L, Roarty E, Lam V, Papadimitrakopoulou V, Wistuba I, Heymach J, Glisson B, Liao Z, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Cancer Discovery. Submitted.

157. Fu S, Wang Y, Wang J, Piha-Paul SA, Janku F, Subbiah V, Shi N, Hess KR, Broaddus RR, Shan B, Naing A, Hong DS, Tsimberidou AM, Karp DD, Lu C, Papadimitrakopoulou V,


Page 24 of 47

Heymach JV, Meric-Bernstam F. Outcome Analysis of Phase I Trial Patients with Metastatic KRAS and/or TP53 Mutant Non-Small Cell Lung Cancer. Clinical Cancer Research. Submitted.

158. Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang J, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V. Pembrolizumab and Platinum-Based Chemotherapy as First-Line Therapy for Advanced NonSmall-Cell Lung Cancer: Phase 1 Cohorts From the KEYNOTE-021 Study. Journal of Clinical Oncology. Submitted.

159. Yang JCH, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou V, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Activating EGFR Mutation. Journal of Thoracic Oncology. Submitted.

160. Koo JS, Lee JW, Zhang Y, Sharma R, Sanmamed MF, Wu J, Choi JJ, Park HS, Iwasaki A, Kaftan EJ, Chen L, Papadimitrakopoulou V, Herbst RS. The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. Clinical Cancer Research. Submitted.

Invited Articles 1. Papadimitrakopoulou VA, Shin DM, Hong WK. Molecular and cellular biomarkers for field

cancerization and multistep process in head and neck tumorigenesis. Cancer Metastasis Rev 15(1):53-76, 3/1996. PMID: 8842479.

2. Papadimitrakopoulou VA, Hong WK. Biology of oral premalignant lesions: concepts and implications for chemoprevention. Eur J Cancer Prev (Supp 2):8-93, 12/1996. PMID: 9061300.

3. Papadimitrakopoulou VA, Hong WK. Retinoids in head and neck chemoprevention. Proc Soc Exp Biol Med 216(2):283-90, 11/1997. PMID: 9349698.

4. Papadimitrakopoulou VA, Hong WK. Retinoids in head and neck chemoprevention. Proc Soc Exp Biol Med 216(2):283-90, 1997. PMID: 9349698.

5. Geyer C, Papadimitrakopoulou V, Hong WK. Chemoprevention in head and neck cancer: basic science and clinical application. Semin Radiat Oncol 8(4):292-301, 10/1998. PMID: 9873107.

6. Papadimitrakopoulou V, Ayoub JP, Hong WK. New development in the chemoprevention of lung cancer. Primary Care and Cancer 18:51-56, 1998.

7. Papadimitrakopoulou VA, Hong WK. Combined-modality therapy in paranasal sinus cancer. Cancer J Sci Am 5(4):208-10, Jul-Aug, 7/1999. PMID: 10439164.

8. Papadimitrakopoulou VA. Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal. Curr Opin Oncol 12(3):240-5, 5/2000. PMID: 10841196.

9. Papadimitrakopoulou VA, Hong WK. Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer. Int J Cancer 88(6):852-5, 12/2000. PMID: 11093804.

10. Papadimitrakopoulou VA. Chemoprevention of head and neck cancer: an update. Curr Opin Oncol 14(3):318-22, 5/2002. PMID: 11981278.

11. Glover KY, Papadimitrakopoulou VA. Chemoprevention of head and neck cancer. Curr Oncol Rep 5(2):152-7, 2003. PMID: 12583833.

12. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 5(4):311-6, 4/2004. PMID: 15093538.

13. Tsao AS, Papadimitrakopoulou VA. The future of NSCLC molecular profiles guiding treatment decisions. Comment on "ALK-Targeted Therapy for Lung Cancer. Ready for Prime Time. Oncology (Williston Park) 25(7):607, 614, 6/2011. PMID: 21888260.

14. Tsao AS, Papadimitrakopoulou V. Mitotic Inhibitors. J Thorac Oncol 6(11 Suppl 4):S1789-90, 11/2011. PMID: 22005531.

15. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in Lung Cancer. Transl Lung Cancer Res 3(1):53-63, 2/2014. PMCID: PMC4367607.

16. Skoulidis F, Papadimitrakopoulou VA. Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-small Cell Lung Cancer. Clin Cancer Res. e-Pub 11/2016. PMID: 27821604.


Page 25 of 47

17. Skoulidis F, Papadimitrakopoulou VA. Personalized medicine tackles clinical resistance : Alectinib in ALK-positive non-small cell lung cancer progressing on first generation ALK inhibitor. Clinical Cancer Research. Submitted.

Editorials 1. William WN, Papadimitrakopoulou VA. Optimizing Biomarkers and Endpoints In Oral Cancer

Chemoprevention Trials. Cancer Prev Res (Phila) 6(5):375-8, 5/2013. PMCID: PMC3683314. Other Articles

N/A Abstracts

1. Papadimitrakopoulou V, Shin DM, Clayman G, El Naggar A, Martinez L, Gillenwater A, Goepfert H, Hong WK. Biochemoprevention or advanced premalignant lesions in the upper aerodigestive tract. Seventh International Congress on anti-cancer treatments. Paris, France,:P386, 2/1997.

2. Papadimitrakopoulou V, Shin DM, Clayman G, El-Naggar A, Shin HJ, Lippman SM, Martinez L, Gillenwater A, Callender D, Gopfert H, Hong WK. Efficacy of biochemoprevention in reversal of advanced premalignant lesions (PLs) of the upper aerodigestive tract (UADT). Proc Am Soc Clin Oncol 16:1366, 1997.

3. Papadimitrakopoulou V, Izzo JG, Lippman SM, Lee JS, Fan YH, Clayman G, Ro JY, Hittelman WN, Lotan R, Hong WK, Mao L. Frequent inactivation of p16INK4a in oral premalignant lesions. Proc Am Assoc Cancer Res 38:1646, 1997.

4. Shin DM, Mao L, Papadimitrakopoulou V, El-Naggar A, Clayman G, Shin HJ, Lee JS, Lippman SM, Gillenwater A, Hittelman WN, Hong WK. Modulation of biomarkers with chemopreventive therapy in advanced premalignant lesions in the upper aerodigestive tract. Proc Am Soc Clin Oncol 16:1557, 1997.

5. Sarris AH, Papadimitrakopoulou V, Dimopoulos MA, Braunschweig I, Smith T, Pugh WC, Rodriguez MA, Ha C, Callender D, Cox J, McLaughlin P, Cabanillas F. Primary parotid lymphoma: the effect of International Prognostic Index on outcome. Proc Am Soc Clin Oncol 16:65, 1997.

6. Geyer C, Papadimitrakopoulou V, Lee JS, Lippman S, Xu XC, Lee J, Hong WK, Lotan R. A lack of association among the basal level of retinoic acid receptor b (RARb) MRNA in oral premalignant lesions (OPLS), its upregulation by 13-cis-retinoic acid (13cra) and cancer development during a long-term follow-up. Proc Am Soc Clin Oncol 17:1506, 1998.

7. Izzo J, Papadimitrakopoulou V, Mao L, Ro JY, Hong WK, Hittelman WN. Cyclin D1 (CCND1) overexpression and 9p21 loss promote CCND1 amplification and p53 alterations during head and neck (HNSC) tumorigenesis. Proc Am Assoc Cancer Res 39:2377, 1998.

8. Mao L, Fan YH, Shin DM, Papadimitrakopoulou V, El-Naggar AK, Izzo GJ, Lee JS, Clayman G, Shin HJ, Hittelman WN, Lippman SM, Hong WK. Loss of heterozygosity (LOH) at 9p21 is frequent in head and neck preneoplastic lesions (HNPLs) and independent of clinical parameters. Proc Am Assoc Cancer Res 39:2453, 1998.

9. Papadimitrakopoulou V, Khuri FR, Lippman SM, Shin DM, Ginsberg L, Glisson BS, Martinez L, Loewen G, Truglia J, Hong WK. Phase I/II evaluation of targretin (LGD 1069), a novel, RXR-specific retinoid, in patients with recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 17:1512, 1998.

10. Papadimitrakopoulou V, Oh Y, El-Naggar A, Izzo J, Clayman G, Hong WK, Mao L. Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. Proc Am Assoc Cancer Res 39:2330, 1998.

11. Papadimitrakopoulou V, Shin DM, Clayman G, El-Naggar A, Myers J, Lewin J, Lawhorn K, Gillenwater A, Diaz E, Goepfert H, Hong WK. Biochemoprevention for advanced premalignant lesions (APL) of the upper aerodigestive tract (UADT): a promising biologic approach for laryngeal dysplasia. Proc Am Soc Clin Oncol 18:1525, 1999.

12. Papadimitrakopoulou V, Izzo J, Keck JM, Mao L, El-Naggar AK, Shin DM, Hittelman WN, Hong WK. Biochemoprevention for dysplastic aerodigestive tract lesions: effects of cyclin D1 and p16 abnormalities. Proc AACR-NCI-EORTC Int Conf 5:3866s:684, 1999.


Page 26 of 47

13. Papadimitrakopoulou V, Izzo J, Keck J, Mao L, El-Naggar A, Shin DM, Hittelman WN, Hong WK. Biochemoprevention-effects on cell cycle regulation. Proc Am Assoc Cancer Res 40:2832, 1999.

14. Izzo J, Papadimitrakopoulou V, El-Naggar A, Lee JJ, Hong WK, Hittelman WN. Detection of clonal genetic events preceding tetraploidization and cyclin D1 (CCND1) gene amplification during head and neck (HNSCC) tumorigenesis. Proc Am Assoc Cancer Res 40:945, 1999.

15. Shin DM, Mao L, Papadimitrakopoulou V, Clayman G, El-Naggar A, Shin HJC, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK. Modulation of the p53 gene and protein and pathologic responses to biochemoprevention in patients with advanced premalignant lesions. Proc Am Assoc Cancer Res 40:4124, 1999.

16. Herbst RS, Khuri FR, Jung M, Fossella FV, Lee JS, Glisson BS, Shin DM, Pisters KM, Papadimitrakopoulou V, Kurie JM, Perez-Soler R, Liu D, Munden R, Hong WK. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Proc Am Soc Clin Oncol 18:1782, 1999.

17. Shin DM, Khuri FR, Glisson BS, Reyes J, Ginsberg L, Papadimitrakopoulou V, Herbst R, Lee JJ, Goepfert H, Lippman SM, Hong WK. Phase II study of paclitaxel, ifosfamide, and carboplatin (TIC) in patients (PTS) with recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 18:1521, 1999.

18. Izzo J, Koster MI, Papadimitrakopoulou V, El-Naggar AK, Hong WK, Hittelman WN. Fragile site (FRA) upregulation defines a distinct pathway of head and neck (HN) tumorigenesis. Proc Am Assoc Cancer Res 41:69:443, 2000.

19. Hittelman WN, Papadimitrakopoulou V, El-Naggar AK, Clayman G, Myers J, Lee JS, Corrales C, Lee JJ, Hong WK, Shin DM. High genetic instability is associated with poor therapeutic outcome following biochemopreventive treatment of advanced premalignant lesions (APL) of the larynx and oral cavity. Proc Am Assoc Cancer Res 41:223:1421, 2000.

20. Papadimitrakopoulou V, Mao L, Izzo JG, Keck J, Shin DM, El-Naggar AK, Clayman G, Hittelman WN, Hong WK. Multiple mechanisms of p16 inactivation in advanced premalignant lesions (APL) of the upper aerodigestive tract (UADT). Proc Am Assoc Cancer Res 41:223:1422, 2000.

21. Kim KB, Khuri FR, Shin DM, Papadimitrakopoulou V, Terry K, Perez-Soler R, Hong WK. Phase I trial of weekly topotecan and gemcitabine in patients (pts) with solid tumors. Proc Am Soc Clin Oncol 19:220:858, 2000.

22. Papadimitrakopoulou V, Glisson BS, Khuri FR, Lippman SM, Ginsberg LE, Diaz EM, Jr., Lee J, Garden AS, Ang K, Geopfert H, Hong WK, Shin DM. Phase II study of induction chemotherapy with paclitaxel (T), ifosfamide (I) and carboplatin (C) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 19:420:1659, 2000.

23. Hittelman WN, Shin DM, Mao L, Papadimitrakopoulou V, Lee J, El-Naggar AK, Lippman SM, Clayman GL, Myers JN, Shin HJ, Lee JS, Hong WK. Pretreatment biomarkers predict response of advanced head and neck premalignant lesions to biochemoprevention. Proc Am Soc Clin Oncol 19:414:1636, 2000.

24. Izzo J, Babenko I, den Hollander P, Hong WK, Hittelman WN, Papadimitrakopoulou V. . Cyclin D1 genotypes: Impact on expression and risk of cancer development in the upper aerodigestive tract. Proc Am Assoc Cancer Res 42:342:1843, 2001.

25. Cohen EEW, Papadimitrakopoulou V, Silverman S, Jesse M, Thomas M, Kirn D, Hong WK, Vokes EE, Rudin CM. . A Phase II Trial of an Attenuated Adenovirus, Onyx-015, as Mouthwash Therapy for Premalignant Oral Dysplasia. Proc Am Soc Clin Oncol 20:229a:915, 2001.

26. Tran HT, Blumenschein GR Jr, Madden T, Shin DM, Khuri F, Fossella F, Papadimitrakopoulou V, Lee JS, Haas A, Dordal M, Hong WK, Herbst RS. . Phase I Study of the Angiogenesis Inhibitor TNP-470 in Combination with Paclitaxel (P) and Carboplatin (CPt) in Patients with Solid Tumors. Proc Am Soc Clin Oncol 20:99a:394, 2001.

27. Papadimitrakopoulou V. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics:276, 2001.


Page 27 of 47

28. Papadimitrakopoulou V, Lozada J, Henderson T, Brito R, McGarry W, Glisson B, Herbst RS, Zinner R, Lee JS, Valero V, Hong WK, Khuri FR. A phase II study of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer as front-line and second-line therapy. Proc Am Soc Clin Oncol 20:259b:2789, 2001.

29. Papadimitrakopoulou V, den Hollander P, El-Naggar A, Hittelman WN, Hong WK, Izzo J. Frequent and early alterations in b-catenin expression during head and neck tumorigenesis. Proc Am Assoc Cancer Res 42:576:3090, 2001.

30. Swisher S, Roth J, Komaki R, Hicks M, Ro J, Hong WK, Ahrar K, Correa A, Dolormente M, Dreiling L, Fang B, Fossella F, Francisco R, Glisson B, Herbst R, Huaringa A, Gu J, Kelly J, Kemp B, Khuri F, Kurie J, Lee J, Lee JS, Liao Z, Merritt J, Morice R, Morello F, Mosheim M, Munden R, Papadimitrakopoulou V, Pisters K, Putnam J, Sarabia A, Shelton T, Stevens C, Shin D, Smythe W, Vaporciyan A, Walsh G, Yin M, Yver A. Induction of Pro-Apoptotic Mediators and Tumor Regression Following Intratumoral Delivery of Adenoviral p53 (RPR/INGN 201) and Radiation Therapy in Patients with Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 20:257a:1024, 2001.

31. Glisson BS, Garden A, Shin D, Morrison W, Papadimitrakopoulou V, Clayman G, Khuri F, Schechter N, Eicher S, Goepfert H, Ang KK, Hong WK. Neoadjuvant Cisplatin/5-FU (PF) Followed by Boost Chemoradiation for Advanced T Stage Nasopharyngeal Cancer. Neoadjuvant Cisplatin/5-FU (PF) Followed by Boost Chemoradiation for Advanced T Stage Nasopharyngeal Cancer. Proc Am Soc Clin Oncol 20:232a:926, 2001.

32. Komaki R, Lee JS, Kaplan B, Allen P, Kelly J, Liao Z, Stevens C, Fossella F, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Cox JD. Randomized phase III study of chemoradiation ± amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:325a:1298, 2001.

33. Mandal M, Adam L, Wang RA, El-Naggar A, Papadimitrakopoulou V, Lotan R, Hong WK, Kumar R. . Inhibition of p21-activated kinase 1, directional cell motility and invasion of growth-factor-activated human cancer cells by the selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839. Proc Am Assoc Cancer Res 43:157:786, 2002.

34. Papadimitrakopoulou V, Figlin R, Garland L, Von Hoff D, Kris M, Purdom M. A Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in patients with non-small cell lung cancer who failed prior platinum-based regimens). 14th EORTC-NCI-AACR, Symposium on Molecular Targets and Cancer Therapeutics, Frankfurt, Germany 38:S36:106A, 2002.

35. Papadimitrakopoulou V, Henderson E, Breimer L, Dhingra K, Zhi J, Ritland SR, Lee JS. A phase I clinical and pharmacokinetic study of oral Ro31-7453, a novel cell cycle inhibitor, administered in combination with paclitaxel. Proc Am Soc Clin Oncol 21:6b:1830, 2002.

36. Murren JR, Papadimitrakopoulou V, Sizer KC, Vaidyanathan S, Ravera C, Abbruzzese JL. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166; a novel tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 21:95a:377, 2002.

37. Papadimitrakopoulou V, Kies M, Glisson B, DeMario M, Henderson T, Ritland S. A Phase I study of R0 31-7453, a novel oral cell cycle inhibitor, in combination with paclitaxel: final results. . 14th EORTC-NCI-AACR, Symposium on Molecular Targets and Cancer Therapeutics, Frankfurt Germany 38:S49:151, 2002.

38. Cohen EW, Papadimitrakopoulou V, Silverman SJ, Recant W, El-Naggar A, Hong WK, Freeman S, Vokes EE, Rudin CM7. A Phase II trial of an attenuated adenovirus, ONXY-015, as mouthwash therapy for premalignant dysplastic oral lesions. 14th EORTC-NCI-AACR, Symposium on Molecular Targets and Cancer Therapeutics, Frankfurt Germany 38:S84:272, 2002.

39. Papadimitrakopoulou V, Myers J, Atwell A, Lewin J, El-Naggar A, Hong WK. Biochemoprevention for laryngeal dysplasia: Initial accrual and compliance report. Frontiers in Cancer Prevention Research 99:A320, 2002.

40. Izzo J, Papadimitrakopoulou V, Den Hollander PLC, Liu D, El-Naggar A, Hong WK Hittelman WN. Cyclin D1 A870G polymorphism enhances genomic instability during head and neck tumorigenesis. Proc Am Assoc Cancer Res 43:293:1456, 2002.

41. Massarelli E, Brown E, Tran N, Papadimitrakopoulou V. E-cadherin expression is lost early in head and neck tumorigenesis. Frontiers in Cancer Research 123:B315, 2002.


Page 28 of 47

42. Johnson FM, Kurie JM, Pisters KM, Fossella FV, Peeples BO, Papadimitrakopoulou V, Blumenschein GR, Kies MS, Komaki R, Glisson BS. Phase I trial of weekly etoposide (E), cisplatin (P), and irinotecan (I) with G-CSF in patients with small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 21:213a:1244, 2002.

43. Henner WD, Figlin RA, Garland LL, Von Hoff D, Gitlitz BJ, Purdom M, Martin E, Brown GL, Dombroski J, Maack C, Macpherson J, Woodrow P, Kyle P, Nichois A, Papadimitrakopoulou V. Phase II study of TLK286 (GST PI-1 activated glutathione analog) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:313a:1249, 2002.

44. Komaki R, Lee JS, Milas L, Kaplan B, Allen P, Liao Z, Stevens CW, Fossella FV, Zinner RG, Papadimitrakopoulou V, Khuri F, Herbst RD, Kies MS, Blumenschein GR, Glisson B, Hong WK, Morice R, Cox JD. Phase III Trial of Amifostine With Chmoradiation for Inoperable Non-Small Cell Lung Cancer (NSCLC): Does Amifostine Protect Cancer Cells? Am Soc Therapeut Rad Oncol:8909, 2002.

45. Khuri F, Gillenwater A, Diaz E, Lewin J, Shin D, Glisson BS, Herbst RS, Steinhaus G, Altamirano E, Taylor S, Clayman G, Myers J, Papadimitrakopoulou V, Lippman S. Pilot trial of paclitaxel, ifosfamide and cisplatin (TIP) as induction or exclusive therapy for intermediate to advanced laryngeal cancer. Proc Am Soc Clin Oncol 21:277a:906, 2002.

46. Papadimitrakopoulou V, Tran N, Den-Hollander P, Hong WK, Izzo J. Role of E-cadherin complex abnormalities in carcinogenic progression of head and neck premalignant lesions. Proc Am Assoc Cancer Res 43:311:1544, 2002.

47. Jones SF, Burris HA, Kies M, Willcutt N, Degen P, Bai S, Mauro D, Decillis A, Youssoufian H, Papadimitrakopoulou V. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. ASCO, 39th Annual Meeting, Chicago, IL 199:2011, 2003.

48. Johnson FM, Garden A, Kies M, Clayman G, Brumfield B, Khuri F, Morrison W, Papadimitrakopoulou V, Diaz E, Glisson B. A phase II study of docetaxel (D) and carboplatin (C) as neoadjuvant therapy for patients with low T, high N stage nasopharyngeal carcinoma (NPC). ASCO, 39th Annual Meeting, Chicago, IL 22:510:2053, 2003.

49. Massarelli E, Liu D, El-Naggar A, Hong WK, Papadimitrakopoulou V. Akt activation correlates with adverse outcome in tongue cancer. American Society of Clinical Oncology (ASCO) 39th Annual Meeting, Chicago, IL, 2003.

50. Massarelli E, Liu D, El-Naggar A, Hong WK, Papadimitrakopoulou V. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104(11):2430-6, 2003. PMID: 16245318.

51. Zinner R, Obasaju CK, Fossella FV, Papadimitrakopoulou V, Pisters KMW, O'Day MR, Peeples BO, Hatfield AK, Hong AK, Herbst RS. Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): A phase II trial. ASCO, 39th Annual Meeting, Chicago, IL 22:642:2580, 2003.

52. Papadimitrakopoulou V, Brown E, Liu D, El-Naggar A, Hong WK. IGFPBP Loss predicts for adverse outcome in head and neck squamous cell carcinoma. 94th Annual Meeting, American Association for Cancer Research, Washington, D.C.:2019, 2003.

53. Glover KY, Ginsberg L, Garden A, Glisson B, Diaz E, Kies M, Clayman G, Goepfert H, Hong W, Papadimitrakopoulou V. Intraarterial cisplatin, intravenous paclitaxel, and ifosfamide as an organ preservation approach in paranasal sinus squamous cell cancer. ASCO, 39th Annual Meeting, Chicago, IL 22:505:2034, 2003.

54. Papadimitrakopoulou V, Figlin R, Garland L, Blumenschein G, Fossella F, Von Hoff DD, King L, Brown GL, Mascavage J, Henner WD. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with non-small cell lung cancer (NSCLC) who failed prior platinum-based regimens. ASCO, 39th Annual Meeting, Chicago, IL 22:655:2636, 2003.

55. Glisson B, Garden A, Kies M, Schechter N, Myers J, Zentgraf R, Papadimitrakopoulou V, Lewin J, Clayman G, Ang K-K. Phase II study of docetaxel (D), cisplatin (P), and concomitant boost radiation (CB-RT) for patients with locally advanced squamous cancer of the head and neck (SCHN). ASCO, 39th Annual Meeting, Chicago, IL 22:500:2011, 2003.

56. Kurup A, Hanna N, Falk S, O'Brien M, Von Pawel J, Gatzemeier U, Papadimitrakopoulou V, Rosso R, Demario M, Dhingra K. Phase II study of Ro 31-7453 in patients with recurrent


Page 29 of 47

stage III with pleural effusion or stage IV non small cell lung cancer (NSCLC). ASCO, 39th Annual Meeting, Chicago, IL 22:678:2725, 2003.

57. Tsao AS, Kim ES, Nazario A, Fossella FV, Glisson BS, Zinner R, Henderson T, Liu D, Papadimitrakopoulou V, Khuri FR. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer as frontline and second-line therapy. ASCO, 39th Annual Meeting, Chicago, IL 22:691:2779, 2003.

58. Massarelli E, Brown E, Tran N, Papadimitrakopoulou V. Predictive role of p27 loss of protein expression alone and in association with loss of E-cadherin protein expression in preneoplastic lesions of head and neck. Proc Am Ass Can Res (AACR) 1896, 2003.

59. Koshy S, Herbst RS, Obasaju CK, Fossella F, Papadimitrakopoulou V, Pisters KMW, Blumenschein G, Peeples BO, Hong WK, Zinner RG. A phase II trial of pemetrexed (P) plus carboplatin (C) in patients with (pts) with advanced non-small cell lung cancer (NSCLC). ASCO 40th Annual Meeting, New Orleans, Louisiana,:7074, 2004.

60. Papadimitrakopoulou VA, Lnu S, Brown E, Angelaki S. Combined effects of inhibition of mTOR and EGFR signaling on apoptosis and kinase pathways in non-small cell lung cancer cell lines. AACR 95th Annual Meeting, Orlando, Florida:4833, 2004.

61. Izzo JG, Hittelman WN, Liu DD, Lee JJ, Wu X, Hong WK, Papadimitrakopoulou VA. Cyclin D1 polymorphism, biochemoprevention and risk of upper aero-digestive tract cancer development. ASCO 40th Annual Meeting, New Orleans, Louisiana:1006, 2004.

62. Letrent S, Callegari F, Wong T, Burris H, Cohen R, Lorusso P, Papadimitrakopoulou V, Shapiro G, Griffin T, Decillis A. Evaluation of a novel RNA biomarker of CDK2 inhibition in phase 1 clinical trials with BMS-387032. ASCO 40th Annual Meeting, New Orleans, Louisiana:2031, 2004.

63. Komaki R, Allen P, Glisson B, Lu C, Kaplan B, Fossella F, Liao Z, Jeter M, Stevens C, Chang J, Blumenschein G, Hong WK, Herbst R, Papadimitrakopoulou V, Kim E, Cox JD. Hyperfractinated and accelerated thoracic radiation therapy (HFXA/TRT) increased survival compared to daily TRT for limited small cell lung cancer (LSCLC) patients treated with concurrent chemotherapy. ASTRO, 2004.

64. Angelaki SI, El-Naggar AK, Brown EN, Lnu S, Ayers GD, Lee JJ, Papadimitrakopoulou VA. Molecular characterization of the P13/Akt pathway in head and neck squamous cell cancer (HNSCC). ASCO 40th Annual Meeting, New Orleans, Louisiana:9643, 2004.

65. Tran HT, Zinner R, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum B, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer (NSCLC). ASCO 40th Annual Meeting, New Orleans, Louisiana:2050, 2004.

66. Papadimitrakopoulou V, Boasberg P, Figlin R, Zinner R, Blumenschein G, King L, Truong M, Patel K, Brown GL, Hanna N. Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC). ASCO 40th Annual Meeting, New Orleans, Louisiana,:7140, 2004.

67. Blumenschein G, Lu C, Kies M, Glisson B, Papadimitrakopoulou V, Zinner R, Kim E, Gillenwater A, Chiao J, Hong W. Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer (SCCHN). ASCO 40th Annual Meeting, New Orleans, Louisiana:5578, 2004.

68. Angelaki S, Lnu S, Brown E, Ayers G, Papadimitrakopoulou VA. Experimental and Molecular Therapeutics 37: Prognostic and Predictive Markers: Synergistic interactions of the Hsp90 inhibitor 17AAGand the PI3K inhibitor LY294002 in non-small cell lung cancer (NSCLC)cell lines involove disruption of Akt and c-raf signalling. AACR Meeting Abstracts, 2005.

69. Papadimitrakopoulou V, Edelman M, Zinner R, Blumenschein G Jr, Jones S, Willcutt N, Keck J, Brown G, Burris H. Phase 1-2 dose-ranging trial of TLK286 (TELCYTA) and cisplatin (C) as first-line treatment in advanced non-small cell lung cancer (NSCLC). 11th World Conference on Lung Cancer, Barcelona, Spain:7126, 2005.

70. Burris HA, Edelman MJ, Stewart D, Fossella F, Jones S, Willcutt N, Keck JG, Brown GL, Papadimitrakopoulou V. Phase II dose-ranging study of TLK286 a novel gluthathione analog prodrug, in combination with cisplatin as first-line treatment in locally advanced or metastatic


Page 30 of 47

non-small cell lung cancer (NSCLC). 2005 ASCO Annual Meeting, Orlando, Florida:7126, 2005.

71. Choe MS, Tighiouart M, Rogatko A, Muller S, Shin HJ, Francisco M, Papadimitrakopoulou VA, Khuri FR, Hong WK, Chen Z, Shin DM. Role of cyclooxygenase-2 (COX-2) expression in tumor progression and survival in the squamous cell carcinoma of the head and neck (HNSCC). 2005 ASCO Annual Meeting, Orlando, Florida:5508, 2005.

72. Boyle JO, Ondrey FG, Nathan CO, Brenner DE, Yueh B, Peterson DE, Dannenberg AJ, Burney K, Lippman SM, Papadimitrakopoulou VA. Clinical Prevention Trials: Organ Site Specific Investigations: Head and Neck Cancers: A double-blind, placebo conrolled, randomized phase II study of celecoxib in patients with oral premalignant lesions (OPL). AACR Meeting Abstracts, 2006.

73. Papadimitrakopoulou VA, Fiorentino S, Naeemuddin M. Experimental and Molecular Therapeutics 38: Novel Antitumor Agents 3: Potent activity of the heat shock protein 90 (Hsp90) inhibitor, 17AAG in head and neck squamous cell carcinoma (HNSCC) lines. AACR Meeting Abstracts, 2006.

74. Papadimitrakopoulou VA. Invited Abstract: Head and Neck Cancer: Risk Assessment and Prevention: Overview of chemoprevention strategies for head and neck cancer. AACR Meeting Abstracts, 2006.

75. Papadimitrakopoulou V. Overview of Chemoprevention in Head and Neck Squamous Cell Cancer: Molecular Screening and Risk Prediction. Workshop on Imaging Science Development for Cancer Prevention and Preemption, 2006.

76. Morrow PH, Glisson BH, Ginsberg LE, Lippman SM, Kies MS, Blumenschein GR, Ayuste RC, Feng L, Papadimitrakopoulou V, Kim ES. A phase I dose escalation study of pemetrexed in patient in advanced head and neck squamous cell cancer (HMSCC). Proc of the 2007 ASCO Annual Meeting, Chicago 25(18S):6055, 2007.

77. Papadimitrakopoulou V, Soria JC, Douillard JI, Giaccone G, Wolf J, Crino L, Cappuzzo F, Sharma S, Gross S, Shepherd FA. A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). Proc. 12th World Congress in Lung Cancer. Seoul, Korea, September 2-6, 2007 (abstract C1-02) S2(8):S359, 2007.

78. Papadimitrakopoulou V, Soria JC, Douillard JY, Giaccone G, Wolf J, Crino L, Capuzzo F, Sharma S, Gross SH, Shepherd FA. A phase II study of RAD001 ® (everolimus) monotherapy in patients (pts) with advanced non-small cancer (NSCLC) failing prior platinum-based chemotherapy © or prior C and EGFR inhibitors (EGFR-I). Proc of the 2007 ASCO Annual Meeting 25(18S):7589, 2007.

79. Kim ES, Kies MS, Glisson BS, Tsao A, Ginsberg LE, Holsinger FC, Burke BJ, Truong M, Papadimitrakopoulou V, Lippman SM. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. Proc of the 2007 ASCO Annual Meeting, Chicago 25(18S):6013, 2007.

80. Papadimitrakopoulou V, Blumenschein GR, Leighi NB, Bennouna J, Soria JC, Burris III HA, Dimitrijevic S, Kunz T, Di Scala L, Johnson BE. A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results. Proc. of the 2008 ASCO annual meeing, Chicago, IL 26 (15S)(8051):436s, 2008.

81. Papadimitrakopoulou, V. Molecular targeting, high risk, and other aspects of chemoprevention in the head and neck. Proc. of the 2008 AACR Annual Meeting, San Diego, CA April 12-16, 2008, 2008.

82. Byers LA, Kies MS, William WN, Hu J, Lee JJ, El_Naggar A, Papadimitrakopoulou V, Myers JN, Lippman SM, Heymach JV. Profiling of cytokines and angiogenic factors (C/AF) in head and neck (HN) cancer correlates circulating biomarkers with clinical outcomes followin infection chemotherapy. Proc. of the 2008 ASCO Meeting, Chicago, IL 26 (15S)(6005):317s, 2008.

83. Papadimitrakopoulou V. Everolimus (RAD001C) in combination with Carboplatin (C) and Paclitaxel (P) as first line treatment for patients (pts) with advanced NSCLC: A phase I trial. Proc. of the 13th World Conference on Lung Cancer, San Francisco,CA (#Abs 7141), 2009.


Page 31 of 47

84. Papadimitrakopoulou V, Frank SJ, Blumenschein GR Jr, Chen C, Kane M, Cohen EE, Langmuir P, Krebs AD, Lippman SM, Raben D. Phase I evaluation of vendetanib with radiation therapy (RT) +/- cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). Proc. of ASCO Annual meeting, Orlando, FL (#6016), 2009.

85. Saintigny P, Zhang L, El-Naggar AK, Papadimitrakopoulou V, Feng L, Lee J, Kim ES, Hong WK, Lippman SM, Mao L. Gene expression profiling of oral preneoplastic lesions (OPL) from a prospective prevention trial. Proc. of the Annual Meeting of the American Society of Clin. Oncology, Chicago, IL 28(15S):426s (#suppl; abstr 5521), 2010.

86. Papadimitrakopoulou V, Guo M, Etzel C, Solomon B, Sturgis EM, Lippman SM, Hong WK, Tsao AS. Human papillomavirus (HPV) transmission from oropharyngeal cancer patients to sexual partners. Proc. of the Annual Meeting of the Society of American Clin. Oncology, Chicago, IL 28(15S):427s (#suppl; abstr 5527), 2010.

87. Leighl NB, Soria J, Bennouna J, Blais N, TRaynor AM, Papadimitrakopoulou V, Klimovsky J, Jappe A, Jehl V, Johnson BE. Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). Proc. of the Annual Meeting of the American Society of Clin. Oncology, Chicago, IL 28(15S):544s (#suppl; abstr 7524), 2010.

88. Yan W, Shih JH, Raso MG, Rodriguez-Canales J, Behrens C, Papadimitrakopoulou VA, Herbst RS, Emmett-Buck MR, Wistuba Ii, Erickson HS. Targeted-therapy related molecular biomaker characterization in NSCLC smokers and never-smokers by a novel qRT-PCR for microdissected tissues methodology. Proc of the 101th Annual Meeting of the American Association of Cancer Research, Washington, DC (#794), 2010.

89. Sano D, Matsumoto F, Valdecanas DR, Zhuo M, Molkentine DP, Papadimitrakopoulou V, Heymach JV, Raju U, Milas L, Myers JN. Treatment with vandetanib can overcome resistance of head and neck squamous cell carcinoma cells to cisplatin and radiation in an orthotopic animal model. Proc. of the 101th Annual Meeting of the American Association of Cancer Research, Washington DC (#369), 2010.

90. Chen N, Raben D, Frank Sj, Blumenschein GR, Kane M, Jimeno A, Langmuir P, Krebs, AD, Lippman SM, Papadimitrakopoulou V. Vandetanib with radiation therapy +- cisplatin in previously untreated head and neck squamous cell carcinoma (HMSCC): Results from an ongoing phase I study. ASTRO Head and Neck Symposium, C Handler, AZ, 2010.

91. Papadimitrakopoulou V, Liu S, Fujimoto J, Wistuba I, Lee JJ, Maron EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein G, Kies M, Hong WK, Stewart DJ, Tsao A. Phase II trial of imatinib and docetaxel in patients with metastatic non-small cell lung cancer. Proc. of the 14th World Conference on Lung Cancer, 2011.

92. Ihle NT, Herbst RS, Kim ES, Wistuba II, Lee JJ, Bluemenschein GR, Tsao AS, Chen L, Zhang S, Alden CM, Tang X, Liu S, Stewart DJ, Papadimitrakopoulou V, Heymach JV, Tran HT, Hicks ME, Erasmus JJ, Gupta S, Minna JD, Larsen J, Lippman SM, Hong WK, Powis G. Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 c;inical trial in advanced non-small cell lung cancer. Proc. of the 102th annual meeting of the American Association for Cancer Research, Orlando, FL 52:231 (#955), 2011.

93. Papadimitrakopoulou V, Heymach JV, Frank SJ, Myers JN, Lin HY, Tran HT, Chen C, Hirsch FR, Langmuir PB, Vasselli JR, Lippman SM, Raben D. Updated clinical and biomarker from a Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Proc of the Annual Meeting of the American Society of Clin. Oncology. Chicago, IL, 2011.

94. Karp DD, Hammeken JM. Taylor SH, Men TY, Steinhaus G, Pisters K, Papadimitrakopoulsou V. Young Women with non-squamous non-small cell lung cancer (NSCLC). J Thor Oncology 6(6S):S1408-S1408, 2011.

95. Hong WK, Kim E, Herbst R, Papadimitrakopoulou V, Gold K, Wistuba I, Lee JJ, Lippman S. Evolution of BATTLE trials at MD Anderson Cancer Center. Proc. of the 4th WIN Symposium on Efficacy of Biomarkers and Personalized Cancer Therapeutics, Paris, France. Ann Oncol 23(5):7-7, 2012.

96. Saintigny P, Lang W, Jelinek J, Pickering CR, Feng L, Frederick ML, Zhang L, Ren H, Lee JJ, Kim ES, Fan YH, El-Naggar AK, Hong WK, Myers J, Papadimitrakopoulou VA, Issa JP,


Page 32 of 47

Lippman SM, Mao L. New DNA methylation markers associated with oral cancer (OC) development (dvlpt). Journal of Clinical Oncology (#suppl; abstr 5524), 2012.

97. Papadimitrakopoulou VA, Wistuba II, Lee JJ, Tsao AS, Kalhor N, Fossella FV, Heymach J, Alden CM, Gettinger SN, Coombes KR, Saintigny P, Tang X, Duffield E, Boyer J, Davis SE, Powis G, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology (#suppl; abstr TPS8118), 10/2013.

98. Tran HT, Melnikova VO, Tsao AS, Fossella FV, Johnson FM, Papadimitrakopoulou VA, Garza M, Neal C, Hasegawa, Kruempel A, Wu G, Richardson K, Lewis ME, Legendre BJ, Anderes KL, Davis DW, Heymach JV. Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using antibody independent method, ApoStream. Journal of Clinical Oncology (#suppl; abstr 11044), 10/2013.

99. Tang X, Xue Y, Su X, Harun N, Cai Y, Behrens C, Papadimitrakopoulou VA, Blowers D, Moran C, Kalhor N, Rice DC, Beran G, Lee JJ, Kilgour E, Wistuba II. Fibroblast growth factor receptor 1 (FGFR1) gene copy number gain in adenocarcinoma and squamous cell carcinoma of the lung. Journal of Clinical Oncology (#suppl; abstr 7552), 10/2013.

100. Massarelli E, Ginsberg LE, Lin H, Tran HT, Lee JJ, Williams MD, Blumenschein GR, Lu C, Kies MS, Papadimitrakopoulou VA. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Journal of Clinical Oncology (#suppl; abstr 6067), 10/2013.

101. Wakelee H, Soria J, Camidge R, Gadgeel SM, Goldman J, Varga A, Solomon B, Papadimitrakopoulou V, Kaur P, Sequist LV. First-In-Human Evaluation Of Co-1686, An Irreversible, Highly Selective Tyrosine Kinase Inhibitor Of Mutations Of Egfr (Activating And T790m). 2014 European Lung Cancer Conference, Geneva, Switzerland, 3/2014.

102. Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, Papadimitrakopoulou VA, Wistuba II, Goswami S, Cortez MA, Welsh J, Kurie JM, Heymach JV. Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers. Journal of Clinical Oncology(32;5s) (#(suppl; abstr 3018)), 2014.

103. Papadimitrakopoulou VA, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Heymach JV, Kalhor N, Gupta S, Gettinger SN, Byers LA, Izzo J, Miller VA, Diao L, Wang J, Wei C, Coombes KR, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology(32;5s) (#(suppl; abstr 8042)), 2014.

104. Sequist LV, Soria JC, Gadgeel SM, Wakelee HA, Camidge DR, Varga A, Solomon BJ, Papadimitrakopoulou VA, Jaw-Tsai SS, Caunt L, Kaur P, Rolfe L, Allen AR, Goldman JW. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). (32;5s) (#(suppl; abstr 8010^)), 2014.

105. William WN, Papadimitrakopoulou VA, Lee JJ, Mao L, Lin H, Gillenwater AM, Martin JW, Cohen EW, Lingen MW, Boyle J, Shin DM, Vigneswaran N, Shinn N, Myers J, El-Naggar AK, Lippman SM. Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC). Journal of Clinical Oncology(32; 5s) (#(suppl; abstr 6007)), 2014.

106. Weidhaas JB, Kim ES, Herbst RS, J Yu, Slack F, Blumenschein GR, Tsao AS, Wistuba II, Lee JJ, Papadimitrakopoulou VA, Hong WK, Heymach JV, Tran HT. The KRAS-variant and treatment response in BATTLE-1. Journal of Clinical Oncology(32:5s) (#(suppl; abstr 8135)), 2014.

107. Sequist L, Goldman J, Wakelee H, Gadgeel S, Camidge R, Yu H, Varga A, Solomon B, Oxnard G, Ou SH, Papadimitrakopoulou V, Chao B, Liu SV, Reckamp K, Spira A, Piotrowska Z, Despain, Karlovich, Yurasov , Soria. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). Journal of Clinical Oncology, 5/2015.

108. Papadimitrakopoulou V, Patnaik A, Borghaei H, Stevenson J, Gandhi L, Gubens M, Yang CH, Sequist LV, Ge JY , Bourque J, Bachman RD, Im E, Gadgeel S. Phase 1 study of pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) in advanced


Page 33 of 47

non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. Journal of Clinical Oncology, 5/2015.

109. Patnaik A, Gandhi L, Borghaei H, Socinski M, Gubens M, Stevenson J, Van Dam Sequist L, Yang CH, Papadimitrakopoulou V, Bourque J, Bachman RD,Yang Ge J, Im E, Gadgeel S. Phase 2 study of pembrolizumab (MK-3475) plus chemotherapy versus chemotherapy alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohort G1. Journal of Clinical Oncology, 6/2015.

110. Varga A, Camidge DR, Sequist LV, Wakelee H, Ou SH, Goldman JW, Papadimitrakopoulou V, Gadgeel S, Mekhail T, Oxnard GR, Socinski M, Solomon B, Yu H, Matheny S, Despain D, Soria JC. Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. 40th ESMO European Cancer Congress, Vienna, Austria (#3009), 2015.

111. Soria JC, Goldman JW, Wakelee H, Gadgeel S, Camidge DR, Solomon B, Yu H, Oxnard GR, Ou SH, Papadimitrakopoulou V, Perol M, Reckamp K, Varga A, Dziadziuszko R, Chouaid C, Cortot A, Do P, Moro-Sibilot D, Poudenx M, Seequist LV. Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. 40th ESMO European Cancer Congress, Vienna, Austria (#3105), 2015.

112. Gadgeel S, Soria JC, Goldman JW, Wakelee H, Camidge DR, Yu H, Varga A, Solomon B, Oxnard GR, Ou SH, Papadimitrakopoulou V, Liu SV, Reckamp K, Spira A, Piotrowska Z, Despain D, Karlovich C, Yurasov S, Sequist LV. Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test. 40th ESMO European Cancer Congress, Vienna, Austria (#3088), 2015.

113. Solomon B, Wakelee H, Sequist LV, Gadgeel S, Soria JC, Goldman JW, Yu H, Camidge DR, Papadimitrakopoulou V, Matheny S, Despain D, Besse B. Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M. 40th ESMO European Cancer Congress, Vienna, Austria (#3104), 2015.

114. Sequist LV1, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. Rociletinib in EGFR-mutated non-small-cell lung cancer. 40th ESMO European Cancer Congress, Vienna, Austria. Submitted, 4/2015. PMID: 25923550.

115. Hong WK, Papadimitrakopoulou V. The BATTLE-2 Trial is extension of BATTLE -1 trial. , 2015.

116. Wakelee HA, Sequist LV, Gadgeel S, Soria JC, Goldman JW, Yu H, Camidge R, Solomon BJ, Matheny S, Despain D, Papadimitrakopoulou V. Rociletinib in NSCLC Patients with Negative Central Testing for T790M in TIGER-X. 16th World Conference on Lung Cancer. Submitted (#951).

117. Papadimitrakopolou V, Gandara DR, Redman M, Hirsch FR, Mack PC, Borghaei H, Langer CJ, Engelman JA, Edelman M, Albain K, Lara Jr P, Aggarwal C, Socinski MA, Sigal EV, Herbst R. MTE02.01 - Patients, Investigators and Pharmaceuticals Working Together to Accelerate Research and Access: The Lung Cancer Master Protocol (Lung-MAP) Clinical Trial. 16th World Conference on Lung Cancer (IASLC). In Press (#1979).

118. Lou Y, Diao L, Cuentas ER, Denning W, Chen L, Fan Y, Rodriguez J, Byers L, Wang J, Papadimitrakopoulou V, Behrens C, Wistuba II, Hwu P, Heymach J, Gibbons D. EMT Is Associated with an Inflammatory Tumor Microenvironment with Elevation of Immune Checkpoints and Suppressive Cytokines in Lung Cancer. 16th World Conference on Lung Cancer. Submitted (#2134).

119. Gandara DR, Redman M, Herbst R, Abrams J, Malik S, Sigal E, Hirsch FR, Mack PC, Papadimitrakopoulou V. Lung Master Protocol in Squamous Cell Lung Cancer (Lung-MAP, S1400). 16th World Confernce on Lung Cancer. Submitted (#1800).

120. Tran HT, Elamin Y, Simon GR, Blumenschein GR, Tsao AS, Papadimitrakopoulou V, Gibbons DL, Fossella F, Lanman RB, Banks KC, Byers L, Zhang J, Heymach J. Clinical utilization of a CLIA-certified cell-free DNA (cfDNA) blood test for identification of targetable molecular alterations in patients with non-small cell lung cancer (NSCLC). 2016 ASCO Annual Meeting. Submitted (#e23064).


Page 34 of 47

121. Papadimitrakopoulou V, Redman M, Gandara DR, Hirsch F, Mack P, Borghaei H, Langer C, Wade J, Edelman M, Albain K, Lara Jr P, Aggarwal C, Socinski M, Gettinger S, Bazhenova L, Malik S, Miller V, McDonough S, Sigal E, Kelly K, Herbst R. Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers. 2016 ASCO Annual Meeting. Submitted (#9088).

122. Gadgeel SM, Stevenson J, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens MA, Hauke RJ, Yang JC, Sequist LV, Bachman RD, Ge JY, Raftopoulos H, Papadimitrakopoulou V. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. 2016 ASCO Annual Meeting. Submitted (#9016).

123. Papadimitrakopoulou V, Cappuzzo F, Jotte RM, Reck M, Mok T, Sandler A, Waterkamp D, Coleman S, Sugitani Y, Socinski MA. Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC. 2016 ASCO Annual Meeting. Submitted (#TPS9103).

124. Goldman JW, Soria JC, Wakelee HA, Camidge DR, Gadgeel SM, Yu HA, Reckamp KL, Papadimitrakopoulou V, Perol M, Ou SI, Matheny SL, Despain D, Isaacson JD, Yurasov S, Rolfe L, Sequist LV. Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC). 2016 ASCO Annual Meeting. Submitted (#9045).

125. Wakelee H, Melnikova V, Karlovich CA, Gadgeel SM, Reckamp K, Goldman JW, Camidge DR, Perol M, Ou SI, Liu SV, Yu H, Socinski MA, Mekhail TM, Solomon B, Natale R, Otterson GA, Papadimitrakopoulou V, Soria J, Langer C, Neal JW, Despain D, Yurasov S, Litten J, Raponi M, Erlander M, Sequist LV. A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma. IASLC 17th World Conference on Lung Cancer. Submitted (#4637).

126. Lam VK, Tran HT, Banks KC, Rinsurongkawong W, Papadimitrakopoulou V, Wistuba I, Futreal A, Lanman RB, Swisher S, Talasaz A, Heymach J, Zhang J. Circulating Tumor DNA (ctDNA)-Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC). IASLC 17th World Conference on Lung Cancer. Submitted (#5393).

127. Skouldis F, Elamin YY, Papadimitrakopoulou V, Tong P, Wang J, Lewis J, Rinsurongkawong W, Chu CT, Roarty E, Zhang J, Tran HT, Rodriguez-Canales J, Parra ER, Behrens C, Kadara H, Wistuba I, Heymach J. Impact of Major Co-Mutations on the immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy. IASLC 17th World Conference on Lung Cancer. Submitted (#6343).

128. Papadimitrakopoulou V, Redman M, Gandara DR, Hirsch F, Mack P, Borghaei H, Langer C, Wade J, Edelman M, Albain K, Lara Jr P, Aggarwal C, Socinski M, Gettinger S, Bazhenova L, Malik S, Miller V, McDonough S, Sigal E, Kelly K, Herbst R. Lung-MAP (S1400) Lung Master Protocol: Accural and Genomic Screening Updates. 17th World Conference on Lung Cancer IASLC. Submitted (#3995).

129. Papadimitrakopoulou V, Redman M, Gandara DR, Hirsch F, Mack P, Borghaei H, Langer C, Wade J, Edelman M, Albain K, Lara Jr P, Aggarwal C, Socinski M, Gettinger S, Bazhenova L, Malik S, Miller V, McDonough S, Sigal E, Kelly K, Herbst R. Lung-MAP (S1400) Lung Master Protocol: Accural and Genomic Screening Updates. IASLC 17th World Conference on Lung Cancer. Submitted (#3995).

130. Langer C, Gadgeel SM, Borghaei H, Papadimitrakopoulou V, Patnaik A, Powell S, Gentzler RD, Martins RG, Stevenson JP, Jalal S, Panwalker A, Yang JC, Gubens M, Sequist, Fiore J, Ge J, Raftopoulous H, Gandhi L. Pembrolizumab + Carbboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non-Small Cell Lung Cancer: KEYNOTE-021 Cohort G. IASLC 17th World Conference on Lung Cancer. Submitted (#5787).

131. Papadimitrakopoulou V, Wu YL, Ahn M, Ramalingam SS, Garassino MC, Kim HR, Shepherd F, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Marotti M, Ghiorghiu S, Mok T. Randomised Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3). IASLC 17th World Conference on Lung Cancer. Submitted (#4452).

132. Tran HT, Zhang J, Vasquez M, Fossella FV, Simon GR, Tsao A, Gibbons DL, Elamin YY, Banks KC, Lanman RB, Papadimitrakopoulou V, Heymach J. Retrospective Review Clinical


Page 35 of 47

Use of cfDNA Blood Test for Identification of Targetable Molecular Alterations in Patients with Lung Cancer. IASLC 17th World Conference on Lung Cancer. Submitted (#5969).

Book Chapters 1. Papadimitrakopoulou V, Spiliotis I. Mediastinal tumors. In: Clinical problems in surgery.

Voulgaris Editions: Greece, 83-88, 1989. 2. Papadimitrakopoulou V, Weber D. Multiple Myeloma and Other Plasma Cell Dyscrasias. In:

Medical Oncology. A Comprenhensive Review. PRR Huntington,: New York, 127-38, 1995. 3. Papadimitrakopoulou V, Hong WK. Biology and Chemoprevention of Head and Neck

Cancer. Advances in Basic Research. In: Excerpta Medica International Congress Series 1114. Ed(s) Werner JA, Lippert BM, Rudert HH (eds). Elsevier Science: Amsterdam, Netherlands, 613-28, 1996.

4. Papadimitrakopoulou V, Hong WK. Biomarkers as intermediate endpoints in chemoprevention trials-Biological basis of lung cancer prevention. In: Clinical and Biological Basis of Lung Cancer Prevention.. Ed(s) Martinet Y, Hirsch FR, Martinet N, Vignaud JM and Mulshine J (eds). Birkhäuser Verlag: Swirtzerland, 305-11, 1997.

5. Papadimitrakopoulou V, Hong WK. A brief review of cancer chemoprevention. In: Oncologic Therapies. Ed(s) Vokes E, Golomb H (eds). Springer-Verlag, 1999.

6. Papadimitrakopoulou V, Hong WK. Head and Neck Cancer Chemoprevention. Head and Neck Cancer. In: A Multidisciplinary Approach. Ed(s) Harrison LB, Sessions RB, Hong WK (eds). Lippincot-Raven Publishers: Philadelphia, PA, 49-75, 1999.

7. Papadimitrakopoulou V, Hong KW. Molecular genetics of head and neck cancer: Implications for Cancer Chemoprevention. In: Progress in Cancer Therapy, Vol II. Ed(s) Khayat D, Hortobagyi GN. Blackwell Science, 191-205, 1999.

8. Papadimitrakopoulou V. A brief review of cancer chemoprevention. In: Oncologic Therapies, 2nd Edition,. Ed(s) Vokes E, Golomb H (eds). Springer-Verlag: Berlin and Heidelberg, 2003.

9. Papadimitrakopoulou V, Hong WK. Chemoprevention. In: Cancer of the Head and Neck, Fourth Edition. Ed(s) Myers E, Hanna E, Myers J, Suen J (eds). WB Saunders, 737-46, 2003.

10. Papadimitrakopoulou V, Shin DM, Hong WK. Chemoprevention of Head and Neck Cancer. In: Head and Cancer a Multidisciplinary Approach.. Ed(s) Harrison LB, Sessions RB, Hong WK (eds). Lippincott Williams & Wilkins, 985-1000, 2004.

11. Tsao A, Papadimitrakopoulou V. Chemoprevention of Head and Neck Cancer. In: Head and Neck Cancer: A Multidisciplinary Approach. Ed(s) Harrison LB, Sessions RB, Hong WK. Lippincortt Williams & Wilkins, 918-934, 2009.

12. Papadimitrakopoulou, V. Novel Clinical Design Trial Designs for Metastatic Lung Cancer. In: Lung Cancer. Ed(s) Roth JA, Hong WK, Komaki RU. Wiley, 2013.

Books (edited and written) N/A

Letters to the Editor N/A

Manuals, Teaching Aids, Other Teaching Publications N/A

Other Publications N/A

EDITORIAL AND REVIEW ACTIVITIES Editor/Service on Editorial Board(s)

Member, Editorial Board, Journal of Clinical Oncology, 2006-2009 Member, Editorial Board, Clinical Cancer Prevention, 2008-present Member, Targeted Therapies in Oncology, 2013-present

Member of Editorial Review Board Member, Clinical Cancer Prevention, 2008 Member, Oral Oncology, 2009


Page 36 of 47

Member, 2010 ASCO Educational Book, 2010 Member, Annals of Oncology, 2016 Member, Oncogene, 2016 Member, Cancer Discovery, 2016-present Member, Science Translational Medicine, 2017

Journal Reviewer Reviewer, Journal of Thoracic Oncology, 2009 Biomarkers and Prevention Cancer Letters Cancer Research Clinical Cancer Research Head and Neck International Journal of Cancer and Cancer Epidemiology Journal of Clinical Oncology Methods in Molecular Biology

Other Editorial and Review Activities Reviewer, 2009 ASCO Educational Book, 2009 Member, Frontiers in Cancer Prevention Research Conference, 2009 Reviewer, Genetics/Epigenetics of oral epithelial Dysplasia, Annual World workshop of Oral Medicine Proceedings, 2009 External Evaluator Research Proposals funded by the Greek State through the Ministry of Education, Life Long Learning and Religious Affairs, 2010

TEACHING Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching Courses Taught

Lecturer, Novel Therapies for Head and Neck Cancer 2001

Instructor, Molecularly Targeted Prevention in Head and Neck Cancer, Division of Medicine

2002 Lecturer, Novel Therapies for Head and Neck Cancer, MD Anderson Cancer Center Medical Oncology Fellows

2002 Instructor, Targeted Prevention in Head and Neck Cancer

2003 Instructor, Chemoprevention of Head and Neck Cancer Surgery, Course Number: Curriculum Series

2004 Didactic Lecturer, Chemoprevention of Upper Aerodigestive Tract Cancer, MD Anderson Cancer Center Medical Oncology Fellows

2004 Lecturer, Dental Oncology Curriculum Series

2005-present Lecturer, Clinical Testing of Supplements: Trials at The University of Texas MD Anderson Cancer Center, Phase II of Green Tea


Page 37 of 47

2005 Instructor, Head & Neck Surgery. Current Concepts in Head & Neck Surgery.

2005 Training Programs

N/A Other Formal Teaching

N/A Supervisory Teaching

Committees Advisory Committees

N/A Supervisory Committees

N/A Examining Committees

N/A Direct Supervision

Undergraduate and Allied Health Students N/A

Medical Students N/A

Graduate Students N/A

Postdoctoral Research Fellows MDACC, Erminia Massarelli, MD MDACC, Katrina Glover, MD MDACC, Sofia Angelaki, MD

Clinical Residents and Fellows Effrosyni Apostolidou, M.D. Yanyan Lou

Other Supervisory Teaching Mentor, Mentoring Faculty Members, Anne Tsao, MD Mentor, Mentoring Faculty Members, Chad Pecot, MD Mentor, Mentoring Faculty Members, Erminia Massarelli Mentor, Mentoring Faculty Members, Ferdinandos Skoulidis, MD, PhD Mentoring Faculty Members, Jianjun Zhang, MD, PhD Mentoring Faculty Member, Mehmet Altan, MD Mentor, Mentoring Faculty Members, Pierre Saintigny, MD, PhD Mentoring Faculty Memebers, Vincent Lam, MD Mentoring Faculty Members, Xiuning Le, MD Mentoring Faculty Member, Yasir Elamin, MD

Teaching Outside Current Institution Formal Teaching

Courses Taught Lecturer, 1st Scientific Symposium “New Perspectives in Cancer Treatment," New Targeted Therapies in Lung Cancer,", Thessaloniki, Greece


Page 38 of 47

1998 Lecturer, Post Graduate Seminar in Oncology, Prevention of Upper Aerodigestive Tract Cancer & Biomarkers of Upon Aerodigestive Tract Carcinogenesis, Jeraklion, Creta, Greece

2002 Lecturer, Prevention of Upper Aerodigestive Tract Malignancies, AAO-HNSF. Annual Meeting. Early Detection of Head and Neck Cancer, San Diego, CA, AAO-HNSF

2002 Lecturer, Chemoprevention of Head and Neck Cancer. International Symposium on Dietary Factors and Cancer Prevention: Current Premises and Future Promises., Rochester, MN

2004 Lecturer, Head and Neck Cancer Chemoprevention, 9th Annual Oncology Conference, Lake of the Ozarks, MI

2004 Chair at NSCLC Session/Course Organizer, Workshop MDACC Physicians Network. Second Annual Symposium, Kauai, HI

2006 Lecturer, Continuing Medical Education Series Emerging Therapies for Head and Neck Cancer. An Educational Meeting Series, Chicago and New York

2010 Lecturer, Continuing Medical Education Series Management of Adverse Events Associated with EGFR-inhibitor Therapy, Dallas, Texas

2010 Lecturer, EGFR Inhibitors in Head and Neck Cancer, Sixth Annual Oncology Congress, San Francisco, CA

2010 Expert Advisor, Staging Risk Stratification and prognostication in early stage NSCLC, University of Nebraska Medical Center in Houston, Texas

2010 Lecturer, Best of ASCO 2012 China, Chinese Society of Clinical Oncology

2012 Lecturer, Novel targets for lung cancer: How close are we?, Best of ASCO 2012 China Lung Cancer Session, Chinese Society of Clinical Oncology

2012 Lecturer, Strategy for research on lung cancer, Best of ASCO 2012, China Lung Cancer Session, Chinese Society of Clinical Oncology

2012 Lecturer, Evolving Role of Immunotherapy in Lung Cancer, 11th Annual MD Anderson Physician Symposium, National Harbor, MD

2015 Lecturer, Head and Neck Cancer, 2015 Best of ASCO Annual Meeting, Chicago, IL

2015 Training Programs

N/A Other Formal Teaching

N/A Supervisory Teaching


Page 39 of 47

Committees Advisory Committees

N/A Supervisory Committees

N/A Examining Committees

N/A Direct Supervision

Undergraduate and Allied Health Students N/A

Medical Students N/A

Graduate Students N/A

Postdoctoral Research Fellows Research Mentor, Department of Defense Career Development Award application “Exploring the Interaction of Estrogen Receptor Beta and Oncogenic RAS Signaling in Non-Small Cell Lung Cancer", University of Houston, Christoforos Thomas, PhD

Clinical Residents and Fellows N/A

Other Supervisory Teaching N/A

CONFERENCES AND SYMPOSIA Organization of Conferences/Symposia (Include chairing session)

American Society of Clinical Oncology (ASCO), 2005 ASCO Scientific Program Committee, Orlando, FL, Member, 5/2005 American Society of Clinical Oncology (ASCO), Annual Meeting 2006, Atlanta, GA, Chair, 6/2006 American Society of Clinical Oncology (ASCO), 2007 Annual Meeting Session Chair Prevention. Session: Highlights of the Day, Chicago, IL, Lecturer, 6/2007 American Society of Clinical Oncology (ASCO), ASCO Cancer Education Committee: Head and Neck Track, Member, 2009 American Association for Cancer Research (AACR), 2009 AACR Program Committee: Preclinical Prevention Studies Subcommittee of the Prevention Research Section, Denver, CO, Chair, 4/2009 American Society of Clinical Oncology (ASCO), ASCO 45th Annual Meeting, Head and Neck Cancer Poster. Discussion Session, Orlando, FL, Co-Chair, 6/2009 American Society of Clinical Oncology (ASCO), Educational Committee, Head and Neck Track, Chair, 2010 American Society of Clinical Oncology (ASCO), Scientific Committee, Head and Neck Cancer Track, Member, 2010 Cancer Advance Boston: Focus on Innovation, Boston, MA, Moderator, 9/2014 4th AACR-IASLC International Joint Conference, Lung Cancer Translational Science - From the Bench to the Clinic - Program Committee Member, Committee Member, 2015 Hellenic Oncology Research Group: 3rd Annual Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, Moderator, 2/2015 Hellenic Research Group: 3rd Annual Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, Chair, 2/2015


Page 40 of 47

American Society of Clinical Oncology (ASCO), Head & Neck Oral Session, Chicago, IL, Chair, 6/2015 ASCO-AACR, Thoracic Malignancy Meeting, Organizing Committee, 10/2016 Baylor College of Medicine and MD Anderson Cancer Center Joint Symposium, Thoracic Oncology, Houston, TX, Organizing Committee, 2/2017 Baylor College of Medicine/MD Anderson Cancer Center Joint Symposium, Thoracic Oncology, Houston, TX, Committee Member, 2/2017

Presentations at National or International Conferences Invited

Papadimitrakopoulou V, Shin DM, Clayman G, El Naggar A, Martinez L, Gillenwater A, Goepfert H, Hong WK. Biochemoprevention or advanced premalignant lesions in the upper aerodigestive tract, Seventh International Congress on anti-cancer treatments, Paris, France, 2/3/1997 Efficacy of Biochemoprevention in Reversal of Advanced Premalignant Lesions of the Upper Aerodigestive Tract, 33rd Annual Meeting of the ASCO, Denver, CO, 5/1/1997 Biochemoprevention for Advanced Premalignant Lesions of the Upper Aerodigestive Tract, International Conference of the International Society of Differentiation, Houston, TX, 10/1/1998 Multiple mechanisms of p16 inactivation in advanced premalignant lesions (APL) of the upper aerodigestive tract (UADT), 91st Annual Meeting of the AACR, San Francisco, CA, 4/1/2000 Frequent and Early Alterations in B-Catenin Expression during Head and Neck Tumorigenesis, 92nd Annual Meeting of the American Association of Cancer Research, New Orleans, LA, 3/1/2001 Papadimitrakopoulou VA. Methods in Clinical Care, 3rd FECS AACR ASCO Workshop Methods in Clinical Ca, Flims, Switzerland, 6/1/2001 Chemoprevention Trials in Head and Neck Cancer, Head and Neck Intergroup Meeting, Rockville, MD, 12/1/2001 Other EGFR inhibitors: PKI-166, 2nd Annual Opinion Leader Summit, "Targeted Therapies in the Treatment of Lung Cancer," , Scottsdale, AZ, 2/1/2002 IGFBP3 Loss Predicts for Adverse Outcome in Head and Neck Squamous Cell Carcinoma, 94th Annual Meeting of American Association of Cancer Research, Washington, DC, 6/1/2002 Predictive Role of p27 Loss of Protein Expression Alone and In Association with Loss of E-cadherin Protein Expression in Preneoplastic Lesions of Head and Neck, 94th Annual Meeting of American Association of Cancer Research, Washington, DC, 6/1/2002 Prevention of Upper Aerodigestive Tract Malignancies, AAO-HNSF, Annual Meeting, Early Detection of Head and Neck Cancer, San Diego, CA, 9/1/2002 TLK286 Trials NSCLC, 3rd Annual Opinion Leader Summit, "Targeted Therapies in the Treatment of Lung Cancer," , Aspen, CO, 1/1/2003 Molecularly Targeted Chemoprevention of Head and Neck Cancer, 94th Annual Meeting American Association of Cancer, Washington, DC, 7/1/2003 Development of TLK286 for Non-Small Cell Lung Cancer, 2004 Targeted Therapies for the Treatment of Lung Cancer Investigator's Meeting, San Diego, CA, 2/1/2004 Overview of Chemoprevention in Head & Neck Cancer - Molecular Screening and Risk Prediction, 2nd Annual Opinion Leader Consortium on Novel and Targeted Therapies for Head and Neck Cancer, Montego Bay, Jamaica, 2/1/2004 Head and Neck Cancer Workshop, National Cancer Institute, Washington, DC, 5/1/2004 TLK286, 5th International Lung Cancer Congress, Kauai, HI, 7/1/2004


Page 41 of 47

mTOR Inhibitors in Lung Cancer, 5th Annual Targeted Therapies for the Treatment of Lung Cancer, Steamboat Springs, CO, 2/1/2005 Oral Cancer, 10th International Congress on Oral Cancer, Greece, 4/1/2005 mTOR Inhibitors for NSCLC, 6th Annual Targeted Treatment of Lung Cancer, Santa Monica, CA, 1/20/2006 Head & Neck Cancer, 4th Annual Opinion Leader Consortium on Novel and Targeted Therapies for Head, Neck Cancer, Biscayne, FL, 2/1/2006 Cancer Prevention, NCI Workshop Imaging Science Development for Cancer Prevention and Preemption, Gaithersburg, MD, 7/20/2006 Head & Neck Cancer, 4th International Chicago Symposium on Malignancies of the Chest, Head & Neck, Chicago, IL, 10/1/2006 Head & Neck Cancer, Second Annual Head and Neck Cancer Symposium, Philadelphia, PA, 10/1/2006 Cancer Prevention, 5th Annual AACR International Conference Frontiers in Cancer Prevention Research, Boston, MA, 11/1/2006 A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy © or prior C and EGFR inhibitors (EDFR-I). C1: Molecular Targeted Therapy: Beyond EGFR., Oral presentation at 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, Korea, Republic of, 2007 Diagnosis & Therapy. Genetics, Advances and Challenges in Aerodigestive Epithelial Cancer, Charleston, SC, 2/1/2007 Identification of High Risk Cohorts for Head and Neck Cancer Prevention Based on Tissue Markers, ASCO Annual Meeting, Chicago, IL, 1/6/2008 Rad001 Update, 8th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA, 2/21/2008 Papadimitrakopoulou. Erlotinib prevention of oral cancer (EPOC), MD Anderson Cancer Center | IGR Workshop, Institute Gustave Roussy, Houston, TX, 4/11/2008 Chemoprevention in the Era of Personalized Medicine, Recent Advances, AACR Annual meeting Session, San Diego, CA, 4/20/2008 Early Development in Oncology, Novartis Oncology LEAD Summit VI, Montreal, Quebec, Canada, 6/21/2008 Oral Epithelial Dysplasia, American Academy of Oral and Maxillofacial Pathology, San Francisco, CA, 6/24/2008 Oral Epithelial Dysplasia, 90th AAOMS/AAOMP Annual Meeting, American Academy of Oral and Maxillofacial Pathology, San Francisco, CA, 6/24/2008 Targeted Therapy-Angiogenesis Inhibition, Lunch with the Professors, 7th International Conference on Head and Neck Cancer, San Francisco, CA, 7/1/2008 Targeting EGFR Signaling in High-Risk Oral Intraepithelial Neoplasia, 7th International Conference on Head and Neck Cancer, San Francisco, CA, 7/1/2008 Head and Neck Cancer, Third Hellenic Forum of Oncology, Crete, Greece, 7/4/2008 Bridging Prevention and Treatment for Cancer of the Upper Aerodigestive Tract: Molecular Targeting, Department of Cancer Medicine Grand Rounds, Roswell Park Cancer Institute, Buffalo, NY, 12/3/2008 RAD001 Everolimus alone + with CT, 9th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA, 2/18/2009


Page 42 of 47

Everolimus and Erlotinib, 10th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/2010 AZD6244 + MK2206, 11th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/2011 AZD6244 + MK2206, 12th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/2012 Working Group Member: Design of a Disease-specific Master Protocol.. Conference on Clinical Cancer Research, Engelbert Center for the Health Care Reform, ASCO, AACR, Susan G. Komen for the Cure, Washington, DC, 11/14/2012 Co-Chair. Personalizing Lung Cancer Therapy-The BATTLE Program, MDACC, Transatlantic Science Week Sister Institution Network, Houston, TX, 11/15/2012 Treatment of Thoracic and head and Neck Malignancies: A Personal Journey with a View at Novel Concepts, Grand Rounds, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 11/16/2012 A2D4547, 13th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/2013 MK 2206 + AZD 6244, 13th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/2013 Personalizing NSCLC Therapy: BATTLE-2 Program, Molecular Med Tri-Con, San Francisco, CA, 2/11/2013 Personalizing Therapy in NSCLC: the BATTLE programs, 2nd International Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, 4/4/2013 Personalizing therapy in NSCLC: the BATTLE programs, 2nd International Symposium on Thoracic and Upper Aerodigestive Malignancies, Hellenic Society of Medical Oncology (HeSMO), Athens, Greece, 4/6/2013 Papadimitrakopoulou V. "Master protocols for squamous carcinoma," 6th International Conference on Molecular Targeted Therapy in Lung Cancer, Sorrento, Italy, 4/17/2013 Papadimitrakopoulou V. Master protocol for squamous carcinoma, Lung SPORE Workshop, Rockville, MD, 7/10/2013 Papadimitrakopoulou V. Targeting the PI3K/AKT Axis: Picking a Winner, Physician Education Resource LLC, 14th International Lung Cancer Congress, Huntington Beach, CA, 7/25/2013 Papadimitrakopoulou VA. Oral Discussant, 15th World Conference on Lung Cancer, Internation Association for Study of Lung Cancer, Sydney, Australia, 10/2013 Papadimitrakopoulou V, Wistuba I, Lee JJ, Tsao AS, Kalhor N, Fossella F, Heymach JV, White A, Gettinger SN, Coombes KR, Saintigny P, Tang X, Duffield E, Boyer J, Caimiao W, Powis G, Mauro DJ, Rubiin EH, Hong W, Herbst R. BATTLE - 2 Program: A Biomarker - Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non - Small Cell Lung Cancer (NSCLC), International Association for the Study of Lung Cancer, Sydney, Australia, 10/29/2013 Papadimitrakopoulou V, Gandara D, Hirsch F, Sigal E, Redman M, Allen J, Mack P, Wistuba I, Herbst R. Phase II/III Biomarker - Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (SCCA), International Association for the Study of Lung Cancer, Sydney, Australia, 10/29/2013 Papadimitrakopoulou V. Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer, Cambridge Healthtech Institute, Molecular Med Tricon 2014: 10th Annual Clinical Translational Science Meeting, San Francisco, CA, 2/12/2014


Page 43 of 47

Papadimitrakopoulou V. AZD 4547, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/20/2014 Papadimitrakopoulou V. Master Protocol, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/21/2014 Papadimitrakopoulou V. MK 2206 + AZD 6244, IASLC, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/22/2014 Papadimitrakopoulou V. Head & Neck Cancer, Oral Abstract Presentation, ASCO Annual Meeting 2014, ASCO, Chicago, IL, 6/2/2014 Papadimitrakopoulou VA. Response kinetics and modified RECIST with Immune Therapies, Physician Education Resources LLC, 15th Annual International Lung Cancer Congress, Huntington Beach, CA, 8/1/2014 Papadimitrakopoulou VA, Gandara D, Hirsch F, Redman M, Herbst R. PHASE II/III biomarker-driven Master Protocol for second line, Physician Education Resources LLC (PER), 15th Annual International Lung Cancer Congress, Huntington Beach, CA, 8/2/2014 Papadimitrakopoulou VA. Lung Master Protocol, a Phase II/III Study for Second Line Therapy of Advanced Squamous Lung Carcinoma Re-thinking clinical trial design for NSCLC, The US Oncology Network 13th Annual Science Forum, Grapevine, TX, 9/19/2014 Papadimitrakopoulou VA. Lung Master Protocol, a Phase II/III Study for Second Line Therapy of Advanced Squamous Lung Carcinoma Re-thinking clinical trial design for NSCLC, Southwest Oncology Group, Jeri & Noboru Oishi Symposium, Chicago, IL, 10/23/2014 Papadimitrakopoulou VA. Oral Discussant, ASCO, ASTRO, IASLC, University of Chicago, 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, 10/31/2014 Papadimitrakopoulou VA. Master Protocol for Previously Treated Squamous Cell Carcinoma, ASCO, ASTRO, IASLC, University of Chicago, 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, 11/1/2014 Papadimitrakopoulou VA. Molecular Landscapes in Lung Cancer: Landscape in the USA, Hellenic Oncology Research Group, 3rd Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, 2/7/2015 Papadimitrakopoulou VA. Round Table: Emerging Targeted Therapies in NSCLC: Targeted Therapies for Squamous Cell NSCLC, Hellenic Oncology Research Group, 3rd Symposium on Thoracic and Upper Aerodigestive Malignancies, Athens, Greece, 2/7/2015 Papadimitrakopoulou VA. EFGR: 3rd Generation: AC 001 MA, International Association of the Study of Lung Cancer (IASLC): 15th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/19/2015 Papadimitrakopoulou VA. MEK/AKT/KRAS: MK 2206 (AKT), International Association of the Study of Lung Cancer (IASLC): 15th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/20/2015 Papadimitrakopoulou VA. FGFR +/- VEGFR, PDGFR/Angiogenesis: AZD 4547, International Association of the Study of Lung Cancer (IASLC): 15th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2/21/2015 Papadimitrakopoulou VA. Current ECOG, CALGB and SWOG Clinical Trials, Individualized Therapies Incorporating Novel Agents for Non-Small-Cell Lung Cancer and Breast Cancer, CancerNet, Houston, TX, 4/3/2015 Head and Neck Cancer, ASCO Annual Meeting, ASCO, Chicago, IL, 6/1/2015 Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers, Poster Presentation, ASCO Annual Meeting, ASCO, Chicago, IL, 6/1/2015 Lung Cancer - Non-Small Cell Metastatic, ASCO Annual Meeting, ASCO, Chicago, IL, 6/1/2015


Page 44 of 47

Evolving Role of Immunotherapy in Lung Cancer, 11th Annual MD Anderson Physician Symposium, National Harbor, MD, 7/25/2015 Head and Neck Cancer, 2015 Best of ASCO Annual Meeting, ASCO, Chicago, IL, 8/29/2015 Immunotherapy, 16th World Conference on Lung Cancer, IASLC, Denver, CO, 9/7/2015 Papadimitrakopoulou VA. The Lung Cancer Master Protocol (Lung-MAP) clinical trial, 16th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Denver, CO, 9/7/2015 Medical Oncology Update, 4th Lung Cancer Network, European Society for Medical Oncology (ESMO), Athens, Greece, 1/15/2016 Medical Oncology Update, 4th Lung Cancer Network: From the Bench to the Bedside, Oncology Center of Biomedical Education and Research, Athens, Athens, Greece, 1/15/2016 Immune Activation and Checkpoint Inhibition, 4th Lung Cancer Network: From the Bench to the Bedside, Oncology Center of Biomedical Education and Research, Athens, Athens, Greece, 1/16/2016 Immunotherapy: Immune Activation and Checkpoint Inhibition, 4th Lung Cancer Network, European Society for Medical Oncology (ESMO), Athens, Greece, 1/16/2016 EGFR: AC 0010MA, 16th Annual Targeted Therapies of Treatment of Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/18/2016 FGFR+VEGFR+PDGFR: AZD 4547, 16th Annual Targeted Therapies of Treatment of Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/19/2016 The Role in 1-Line, 10th International Experts Panel Meeting "Immunotherapy of Non Small Cell Lung Cancer," Associazione Italiana di Oncologia Toracica (AIOT), Sperlonga, Italy, 5/6/2016 Lung Cancer - Non-Small Cell Metastatic, ASCO Annual Meeting, American Society of Clinical Oncology (ASCO), Chicago, IL, 6/4/2016 Innovative Clinical Trials: The LungMAP Study, 1st International Symposium on Current and Future Clinical Biomarkers of Cancer: Innovation and Implementation, Norwegian University of Science and Technology, Trondheim, Norway, 6/17/2016 Papadimitrakopoulou V. Randomised Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3), 17th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Vienna, Austria, 12/6/2016 Adaptive Clinical Trial Designs, 17th World Conference on Lung Cancer, Interanational Association for the Study of Lung Cancer (IASLC), Vienna, Austria, 12/7/2016 Oral Session: Avitinib, 17th Annual Targeted Therapies of Lung Cancer Meeting, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/23/2017 Oral Session: AZ4547, 17th Annual Targeted Therapies of Lung Cancer Meeting, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/24/2017 Oral Session: Immunotherapeis and Targted Therapies in Advanced NSCLC, ELCC 2017, European Lung Cancer Conference, Geneva, Switzerland, 5/6/2017 Poster Session: Targeted Therapies and Immunotherapies, ELCC 20147, European Lung Cancer Conference, Geneva, Switzerland, 5/7/2017 Oral Session: Osimertinib in 2nd Line of EGFR Mut+ve Patients, 11th International Experts Panel Meeting: Second Line Treatment Options in Non-Small Cell Lung Cancer: 10 Yrs Later, Associazione Italiana Oncologia Toracica (AIOT), Sperlonga, Italy, 5/12/2017


Page 45 of 47

Poster Session: Lung Cancer-Non-Small Cell Metastatic, ASCO Annual Meeting, American Society of Clinical Oncology (ASCO), Chicago, IL, 6/3/2017 New options after the resistance of 1st and 2nd generation TKIs, Challenges of Modern Oncology: Diagnosis, Biomarkers, Treatment, Hellenic Society of Medical Oncology, Kalamata, Greece, 7/7/2017 Why should I start with immunotherapy at 1st line?, Challenges of Modern Oncology: Diagnosis, Biomarkers, Treatment, Hellenic Society of Medical Oncology, Kalamata, Athens, Greece, 7/8/2017 Poster Session: PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies, 18th World Conference Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Yokohama, Yokohama, Japan, 10/17/2017 Medical Oncology Updates, 5th Lung Cancer Network: From the Bench to the Bedside, Hellenic Society: Oncology Center of Biomedical Education and Research, Athens, Greece, 1/19/2018 Emerging Targeted Therapies in NSCLC, 5th Lung Cancer Network: From the Bench to the Bedside, Hellenic Society: Oncology Center Biomedical Education & Research, Athens, Greece, 1/20/2018 EGFR Session. Avitinib/AC0010, 18th Annual Targeted Therapies of Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/22/2018 FGFR/PDGFR/Angiogenesis Session. AZ4547, 18th Annual Targeted Therapies of Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA, 2/24/2018 Clinical Trial Minisymposium. Safety and Activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC, AACR Annual Meeting, American Association of Cancer Research (AACR), Chicago, IL, 4/16/2018 Poster Discussion Session: Lung Cancer-Non-Small Cell Metastatic, ASCO Annual Meeting, American Society of Clinical Oncology (ASCO), Chicago, IL, 6/3/2018 Molecular Tumor Board, 19th Annual International Lung Cancer, Physician Education Resources, LLC (PER), Huntington Beach, CA, 7/26/2018 Worldwide Landscape of Master Protocols in Lung Cancer, 19th Annual International Lung Cancer, Physician Education Resources, LLC (PER), Huntington Beach, CA, 7/26/2018 Optimizing Clinical Trial Designs in Immunotherapy, WCLC 2018: 19th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Toronto, Toronto, Canada, 9/24/2018

Other, Including Scientific Exhibitions Session V: Immunotherapy - 2nd Line. Master Protocols, Lung Cancer Immunotherapy Meeting, International Association for the Study of Lung Cancer (IASLC), Madrid, Madrid, Spain, 3/23/2018

Seminar Invitations from Other Institutions The Path of Women Who Lead, Third WICR Leadership Development Workshop, American Association of Cancer Research, San Diego, CA, 4/12/2008 Molecularly Targeted Therapies and Prevention Approaches for Upper Aerodigestive Tract Cancer, University of Miami/Sylvester Comprehensive Cancer, 3/2009 Oncology meets Immunology, European Thoracic Oncology Platform, Oncology Center of Biomedical Education and Research, Oncology Unit, Athens School of Medicine, Athens, Greece, Greece, 6/2015


Page 46 of 47

Evolving Role of Immunotherapy in Lung Cancer, 11th Annual MD Anderson-Physicans network Symposium, National Harbor, MD, 7/2015 Business Development Advisory Board, Janssen, Janssen, Philadelphia, PA, 9/14/2015 Precision Medicine Studies: Lung-MAP, ALCHEMIST, New Protocols and Resources, Foundation for the National Institute of Health (FNIH), FNIH, Gaithersburg, MD, 10/15/2015

Lectureships and Visiting Professorships Grand Rounds: The Julia and Patricia Kinsbury Lecture, Yale Cancer Center, New Haven, CT, 6/19/2012 Lung Cancer Therapy: A view of current and novel concepts, Winship Cancer Institute of Emory University, Atlanta, GA, 9/1/2012 Grand Rounds, Lung Cancer Therapy: A view of current and novel concepts, Vanderbilt University, Nashville, TN, 10/3/2012 Precision Medicine for NSCLC in the Era of Genomic Profiling and Immunotherapy; Rethinking Trial Designs and Translational Endpoints., Deans Distinguished Lecture Series, Cornell University, Cancer Medicine, New York, NY, 12/12/2014 Grand Rounds: Personalizing Lung Cancer Therapy, The Paradigm and Vision fo the Future, MDACC, Houston, 2/24/2015

Other Presentations at State and Local Conferences N/A

PROFESSIONAL MEMBERSHIPS/ACTIVITIES Professional Society Activities, with Offices Held

National and International American Association for Cancer Research (AACR)

Member, 1997-present Committee Member, Program Committee Cancer Prevention Sub-Committee, 2008 Chair, Program Committee Prevention, 2009 Member, Clinical and Translational Cancer Research Grants and Scientific Review Committee, 2015-2018 Committee Member, Johnson & Johnson Lung Cancer Innovation Science Grants Scientific Review, 2018-present

American Society of Clinical Oncology (ASCO) Member, 1997-present Member, Scientific Program Committe, 2009-2015 Member, ASCO Educational Book, 2009 Member, Cancer Education Committee, 2009 Chair, Scientific Committee, 2010 Member, ASCO University Review Panel, 2017-present

American Association for the Advancement of Science Member, 2000-2015

International Association for the Study of Lung Cancer (IASLC) Member, 2005-present Publications Committee, 2015-present Membership Committee Member, 2017-present

Southwest Oncology Group (SWOG) Member, Lung Committee, 2011-present

Friends of Cancer Research & Engelberg Center for Health Care Reform at Brookings, DC Panelist, 2013

AACR-IASLC: Fourth AACR-IASLC International Joint Conference: Lung Cancer Translational Science – From the Bench to the Clinic


Page 47 of 47

Program Committee Member, 2015 American Lung Association - Lung Cancer Expert Medical Advisory Panel

Member, 2015-present FDA Advisory Committee for Oncologic Drugs

Member, 2015-present Society for Immunotherapy of Cancer (SITC)

Member, Cancer Immunotherapy Guidelines-Lung Cancer (CIG-LC) Task Force, 2015-present

Local/State N/A

UNIQUE ACTIVITIES 1. Steering Committees & National Projects Leading Principal Investigator, Master Lung Protocol SWOG S1400 (a project sponsored by SWOG, Friends of Cancer Research, Foundation for the National Institutes of Health, Federal Drug Administration & National Cancer Institute, 2013-present.

2. Steering Committee –Global Principal Investigator A Phase III Open Label, Randomized Study of AZD9291 versus Platinum Based Doublet Chemotherapy for patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbor a T790M mutation within the EGFR gene (AURA3).

3. Steering Committee - Atezolizumab First Line Lung All Corners Trials - Global Principal Investigator-Atezolizumab + Nab-Paclitaxel + Carboplatin (NCT02367781).

4. Steering Committee - TIGER Studies - Rociletinib - Clovis Oncology.

5. Steering Committee - MYSTIC Study (Durvalumab and Tremelimumab) - AstraZeneca

6. Steering Committee - Lung Cancer Franchise Steering Committee - AstraZeneca

7. Steering Committee- NKTR-214/Nivolumab 1L Lung Steering Committee- Bristol Myers Squibb DATE OF LAST CV UPDATE

8/24/2018

Documents

Vassiliki A. Papadimitrakopoulou, MD CV · CURRICULUM VITAE. Vassiliki A. Papadimitrakopoulou, MD . PRESENT TITLE AND AFFILIATION. Primary Appointment. Professor, Department of Thoracic/Head